Original Article
Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease
N Engl J Med 2006; 354:1567-1577April 13, 2006
- Abstract
Background
In observational studies, lower homocysteine levels are associated with lower rates of coronary heart disease and stroke. Folic acid and vitamins B6 and B12 lower homocysteine levels. We assessed whether supplementation reduced the risk of major cardiovascular events in patients with vascular disease.
Methods
We randomly assigned 5522 patients 55 years of age or older who had vascular disease or diabetes to daily treatment either with the combination of 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 or with placebo for an average of five years. The primary outcome was a composite of death from cardiovascular causes, myocardial infarction, and stroke.
Results
Mean plasma homocysteine levels decreased by 2.4 μmol per liter (0.3 mg per liter) in the active-treatment group and increased by 0.8 μmol per liter (0.1 mg per liter) in the placebo group. Primary outcome events occurred in 519 patients (18.8 percent) assigned to active therapy and 547 (19.8 percent) assigned to placebo (relative risk, 0.95; 95 percent confidence interval, 0.84 to 1.07; P=0.41). As compared with placebo, active treatment did not significantly decrease the risk of death from cardiovascular causes (relative risk, 0.96; 95 percent confidence interval, 0.81 to 1.13), myocardial infarction (relative risk, 0.98; 95 percent confidence interval, 0.85 to 1.14), or any of the secondary outcomes. Fewer patients assigned to active treatment than to placebo had a stroke (relative risk, 0.75; 95 percent confidence interval, 0.59 to 0.97). More patients in the active-treatment group were hospitalized for unstable angina (relative risk, 1.24; 95 percent confidence interval, 1.04 to 1.49).
Conclusions
Supplements combining folic acid and vitamins B6 and B12 did not reduce the risk of major cardiovascular events in patients with vascular disease. (ClinicalTrials.gov number, NCT00106886; Current Controlled Trials number, ISRCTN14017017.)
Media in This Article
Figure 1
Mean (+SD) Plasma Levels of Total Homocysteine, Folate, Vitamin B6, and Vitamin B12.Figure 2
Kaplan–Meier Estimates of the Proportion of Patients with the Composite Primary Outcome of Death from Cardiovascular Causes, Myocardial Infarction, or Stroke.Article Activity
- Article
Numerous studies suggest that homocysteine may be a modifiable risk factor for cardiovascular disease. In experimental studies, homocysteine causes oxidative stress, damages endothelium, and enhances thrombogenicity.1-3 In general, epidemiologic studies show an independent and graded association between homocysteine levels and cardiovascular risk.4-8 The observational data suggest that even mild-to-moderate elevations in homocysteine increase cardiovascular risk; this observation is important, because such increases are common and can easily be corrected with safe and inexpensive therapy. Folic acid is the most important dietary determinant of homocysteine; daily supplementation with 0.5 to 5.0 mg typically lowers plasma homocysteine levels by about 25 percent. Vitamin B12 supplementation of at least 0.4 mg daily further lowers levels by about 7 percent, and vitamin B6 supplements may be particularly important in lowering homocysteine after methionine loading.9,10
We report the results of the Heart Outcomes Prevention Evaluation (HOPE) 2 study, a large, prospective, randomized clinical trial designed to determine whether prolonged administration of folic acid combined with vitamins B6 and B12 reduces the risk of major vascular events in persons at high cardiovascular risk.
Methods
Study Design
HOPE-2 was a randomized, double-blind, placebo-controlled trial evaluating whether therapy with homocysteine-lowering B vitamins reduces the risk of major vascular events in a high-risk population. The trial design has been described previously.11 The study was coordinated by the Population Health Research Institute at McMaster University in Hamilton, Ontario, and sponsored by the Canadian Institutes of Health Research. Study drug and matching placebo were provided by Jamieson Laboratories, Canada. The study sponsors were not involved in the design, execution, analysis, or reporting of the trial results. An independent data and safety monitoring board monitored the safety of the participants and the overall quality and scientific integrity of the study. The study was approved by the ethics review boards of all participating institutions, and all patients provided written informed consent.
Study Population
Men and women 55 years of age or older who had a history of vascular disease (coronary, cerebrovascular, or peripheral vascular) or diabetes and additional risk factors for atherosclerosis were enrolled, irrespective of their homocysteine levels, from countries with mandatory folate fortification of food (Canada and the United States) and countries without mandatory folate fortification (Brazil, western Europe, and Slovakia). Patients who were taking vitamin supplements containing more than 0.2 mg of folic acid per day were excluded. Detailed eligibility criteria have been published previously11 and are provided in the Supplementary Appendix (available with the full text of this article at www.nejm.org).
Study Intervention
Patients were randomly assigned to receive a combined pill containing 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 (active treatment) or matching placebo daily. The study used central telephone randomization. The randomization code was generated with the use of a fixed block size of four, stratified according to center. All study investigators, personnel, and participants were unaware of the randomization procedure and the treatment assignments.
Follow-up and Laboratory Evaluation
After randomization, patients were evaluated every six months to determine their adherence to treatment (by interview and pill count) and identify adverse events and clinical outcomes. Blood samples were collected at randomization, at two years, and at the end of the study in a randomly selected subgroup of patients after an overnight fast, with proportional representation from countries with folate fortification of food and countries without folate fortification and with expected significant differences in dietary habits.
Plasma levels of folate (Roche chemiluminescence method, Roche Diagnostics), vitamin B6 (Chromsystems kit, Instruments and Chemicals), and vitamin B12 (Immulite 2000 Analyzer, Diagnostic Products) were measured at randomization and at two years. Total plasma homocysteine levels were measured (Abbott IMX immunofluorescence method, Abbott) at randomization, at two years, and at the end of the study (average, five years).
Trial Outcomes
The primary study outcome was the composite of death from cardiovascular causes, myocardial infarction, and stroke. Secondary outcomes were total ischemic events (defined as the composite of death from cardiovascular causes, myocardial infarction, stroke, hospitalization for unstable angina, and revascularization), death from any cause, hospitalization for unstable angina, hospitalization for congestive heart failure, revascularization, the incidence of cancer, and death from cancer. Other outcomes included transient ischemic attacks, venous thromboembolic events, and fractures. All primary and secondary outcomes were centrally adjudicated.
Deaths classified as due to cardiovascular causes were unexpected deaths presumed to be due to ischemic cardiovascular disease and occurring within 24 hours after the onset of symptoms without clinical or postmortem evidence of another cause, deaths from myocardial infarction or stroke within 7 days after the event, deaths associated with cardiovascular interventions within 30 days after cardiovascular surgery or within 7 days after percutaneous interventions, and deaths from congestive heart failure, arrhythmia, pulmonary embolism, or ruptured aortic aneurysm. Deaths from uncertain causes were presumed to be due to cardiovascular causes.
Myocardial infarction was diagnosed when two of the following three criteria were met: typical symptoms, increased cardiac-enzyme levels, and diagnostic electrocardiographic changes.12 Stroke was defined as a focal neurologic deficit lasting more than 24 hours. Computed tomography or magnetic resonance imaging was recommended to identify the type of stroke (ischemic or hemorrhagic). When these tools were not available, the stroke was classified as of uncertain type. Cancers (except basal-cell skin cancer) were diagnosed on the basis of pathological (or cytologic) findings or, when pathological data were not available, on the basis of clinical summaries, results of imaging, levels of serum markers, and other diagnostic procedures. Cancers were classified according to the International Classification of Diseases, 9th Revision.
Statistical Analysis
The study was designed to enroll 5000 patients and to average five years of follow-up to allow the detection of a proportional reduction in the risk of the primary outcome of 17 to 20 percent, with a statistical power of 80 percent and 90 percent, respectively, given an annual event rate of 4 percent in the placebo group and a two-tailed α value of 0.05. This enrollment target was also estimated to provide over 80 percent power to detect a 15 percent reduction in the risk of total ischemic events.
All analyses were performed according to the intention to treat and included all randomized patients. Survival curves were estimated according to the Kaplan–Meier procedure and were compared between treatment groups with the log-rank test. Prespecified subgroup analyses involving Cox models were used to evaluate outcomes in patients from regions with folate fortification of food and regions without folate fortification, according to the baseline plasma homocysteine level and the baseline serum creatinine level. Additional exploratory subgroup analyses were conducted to evaluate the consistency of the study results.
Results
Characteristics of the Patients
Between January and December 2000, 5522 patients were recruited at 145 centers in 13 countries: 3982 (72.1 percent) were from countries with folate fortification of food, and 1540 (27.9 percent) were from countries without folate fortification. Of these patients, 2758 were randomly assigned to active treatment with folic acid and vitamins B6 and B12 and 2764 were assigned to placebo. Baseline characteristics are shown in Table 1Table 1
Baseline Characteristics of the Patients. and were generally well balanced between the study groups.Adherence, Adverse Events, and Follow-up
Among those assigned to the active-treatment group, 95.5 percent were still taking the study drug at one year, 94.0 percent were doing so at two years, 92.5 percent at three years, 91.4 percent at four years, and 90.8 percent at five years. The respective figures for the placebo group were 96.0 percent, 93.4 percent, 92.3 percent, 89.9 percent, and 88.5 percent. Use of open-label folic acid supplements ranged from 2.3 to 4.5 percent in the active-treatment group and from 2.2 to 5.5 percent in the placebo group. There were no serious adverse events related to study treatment. The most common reasons for permanently or temporarily discontinuing treatment at any time were the patient's decision (11.1 percent in the active-treatment group, vs. 12.6 percent in the placebo group), physician's advice (1.6 percent vs. 2.0 percent), hospitalization (1.0 percent vs. 0.8 percent), and general malaise (1.0 percent vs. 0.7 percent).
Follow-up averaged five years. A total of 37 patients, 21 in the active-treatment group and 16 in the placebo group, did not complete the study (21 declined to continue, and 16 were lost to follow-up). The vital status of 99.3 percent of patients was ascertained at the end of the study. All patients who declined to continue the study or were lost to follow-up completed at least two clinic visits and were included in the final analysis, with data censored at the time of the last follow-up visit.
Effects of Supplementation on Vitamin and Homocysteine Levels
Plasma vitamin levels and homocysteine levels for the subgroup of patients in whom they were measured are shown in Figure 1Figure 1
Mean (+SD) Plasma Levels of Total Homocysteine, Folate, Vitamin B6, and Vitamin B12.. At randomization, there were no significant differences between the two groups in plasma levels of folate (27.6 nmol per liter [12.2 ng per milliliter] in the active-treatment group and 27.1 nmol per liter [12.0 ng per milliliter] in the placebo group), vitamin B6 (pyridoxal) (61.9 nmol per liter [10.3 ng per milliliter] and 58.1 nmol per liter [9.7 ng per milliliter], respectively), or vitamin B12 (322.2 pmol per liter [436.6 pg per milliliter] and 314.5 pmol per liter [426.1 pg per milliliter], respectively). Mean total plasma homocysteine levels were also similar in both groups (12.2 μmol per liter [1.6 mg per liter] in both). As expected, there were regional differences, with lower folate and higher homocysteine levels in patients from regions that did not require folate fortification of food than in patients from regions that required folate fortification.Values obtained two years after randomization showed that plasma folate and vitamin B12 levels had approximately doubled and vitamin B6 levels had approximately quadrupled in the active-treatment group, with no significant changes in the placebo group (Figure 1). In the active-treatment group, the mean homocysteine level had decreased to 9.9 μmol per liter (1.3 mg per liter) at two years (a decrease of 2.2 μmol per liter [0.3 mg per liter] from baseline) and to 9.7 μmol per liter (1.3 mg per liter) at the end of the study (a decrease of 2.4 μmol per liter [0.3 mg per liter] from baseline). In the placebo group, the mean homocysteine level had increased to 13.2 μmol per liter (1.8 mg per liter) at two years (an increase of 1.1 μmol per liter [0.1 mg per liter] from baseline) and to 12.9 μmol per liter (1.7 mg per liter) at the end of the study (an increase of 0.8 μmol per liter [0.1 mg per liter] from baseline) (Figure 1). As a result, there was a difference of 3.3 μmol per liter (0.4 mg per liter) in the change from baseline in homocysteine levels between the treatment groups at two years and a difference of 3.2 μmol per liter (0.4 mg per liter) at the end of the study. These differences were greater in the regions that did not require folate fortification (3.7 μmol per liter [0.5 mg per liter] at two years and 4.1 μmol per liter [0.6 mg per liter] at the end of the study) than in regions that required folate fortification (3.2 μmol per liter at two years and 2.9 μmol per liter [0.4 mg per liter] at the end of the study).
Primary Outcomes and Deaths from Any Cause
In the active-treatment group, 519 patients (18.8 percent) died of cardiovascular causes or had a myocardial infarction or stroke, as compared with 547 patients (19.8 percent) in the placebo group (relative risk, 0.95; 95 percent confidence interval, 0.84 to 1.07; P=0.41) (Figure 2Figure 2
Kaplan–Meier Estimates of the Proportion of Patients with the Composite Primary Outcome of Death from Cardiovascular Causes, Myocardial Infarction, or Stroke. and Table 2Table 2
Outcomes.). When each of the components of the primary composite outcome was analyzed separately, there were no significant differences between the groups in the rates of death from cardiovascular causes or myocardial infarction (Table 2 and the Supplementary Appendix). Fewer patients in the active-treatment group than in the placebo group had a stroke (111 [4.0 percent] vs. 147 [5.3 percent]; relative risk, 0.75; 95 percent confidence interval, 0.59 to 0.97; P=0.03). The risk of death from any cause was similar in the active-treatment group and the placebo group (relative risk, 0.99 with active treatment; 95 percent confidence interval, 0.88 to 1.13; P=0.94).Secondary and Other Outcomes
Among the prespecified cardiovascular secondary outcomes, total ischemic events occurred in 900 (32.6 percent) patients in the active-treatment group and in 890 patients (32.2 percent) in the placebo group (relative risk, 1.03; 95 percent confidence interval, 0.94 to 1.13; P=0.57) (Table 2). A total of 268 patients (9.7 percent) in the active-treatment group were hospitalized for unstable angina, as compared with 219 (7.9 percent) in the placebo group (relative risk, 1.24; 95 percent confidence interval, 1.04 to 1.49; P=0.02). There were no significant differences between the treatment groups in hospitalization for heart failure and revascularization.
There were no significant differences in incident cancers and deaths from cancer. There were also no significant differences in the rates of transient ischemic attack, venous thromboembolism, or fracture.
Subgroup Analysis
There were no significant treatment benefits with respect to the primary outcome in any of the prespecified or exploratory subgroups evaluated (Figure 3Figure 3
Effect of Folic Acid and Vitamins B6 and B12 on the Primary Outcome in Prespecified and Exploratory Subgroups.). Of particular interest was the treatment effect among patients with high baseline levels of homocysteine. In the top third of the baseline homocysteine distribution (homocysteine ≥12.7 μmol per liter [1.7 mg per liter]), 23.9 percent of the patients in the active-treatment group and 24.0 percent of the patients in the placebo group had a primary-outcome event. Primary event rates also did not differ significantly between the treatment groups among patients in the upper fifth of the baseline homocysteine distribution (≥19.7 μmol per liter [2.7 mg per liter]).We further explored the effect of treatment on stroke. Most strokes (185, or 71.7 percent) were ischemic, 19 (7.4 percent) were hemorrhagic, 48 (18.6 percent) were classified as of uncertain type, and 6 (2.3 percent) were classified as occurring after surgery or an invasive cardiovascular intervention. Ischemic stroke occurred in 81 patients (2.9 percent) in the active-treatment group and 104 (3.8 percent) in the placebo group (relative risk, 0.78; 95 percent confidence interval, 0.58 to 1.04; P=0.10). There were no significant differences in the rates of hemorrhagic stroke. Fewer patients in the active-treatment group than in the placebo group had a nonfatal stroke (84 vs. 117; relative risk, 0.72; 95 percent confidence interval, 0.54 to 0.95; P=0.02). The incidence of fatal stroke was low and not significantly different between the treatment groups. The apparent effect of treatment on stroke did not differ significantly between regions with mandatory folate fortification of food and regions without mandatory folate fortification and between patients with higher as compared with lower baseline total homocysteine levels (upper vs. middle or lower third of the baseline homocysteine distribution).
The baseline homocysteine level (as a continuous measure) was a predictor of cardiovascular events in analyses adjusted for age, sex, and treatment assignment. Hazard ratios for these analyses were 1.03 for the primary outcome (95 percent confidence interval, 1.02 to 1.04), 1.04 for death from cardiovascular causes (95 percent confidence interval, 1.02 to 1.05), 1.02 for myocardial infarction (95 percent confidence interval, 1.01 to 1.04), and 1.03 for stroke (95 percent confidence interval, 1.02 to 1.05).
Discussion
In our study, daily administration of the combination of folic acid, vitamin B6, and vitamin B12 lowered homocysteine levels significantly but did not reduce the incidence of the primary outcome — the composite of death from cardiovascular causes, myocardial infarction, and stroke — during a mean follow-up period of five years. In subgroup analysis, there was no heterogeneity of treatment effects among patients from regions with mandatory fortification of food with folate and regions without mandatory folate fortification and among patients with higher as compared with lower baseline homocysteine levels.
Our findings are consistent with those of the Norwegian Vitamin (NORVIT) trial, reported elsewhere in this issue of the Journal.13 The NORVIT trial evaluated 3749 patients with recent myocardial infarction from Norway, a country without folate fortification of food, and found no significant beneficial effect of combined treatment with folic acid and vitamin B12, with or without vitamin B6, in spite of adequate homocysteine lowering. Similarly, there was no treatment benefit in the Vitamin Intervention for Stroke Prevention (VISP) study14 and in a smaller trial conducted in 593 patients with stable coronary heart disease in the Netherlands.15
On the basis of epidemiologic studies conducted before our study was initiated, many of which were retrospective, our trial was adequately powered to allow the detection of a proportional reduction in the risk of the primary outcome of 17 to 20 percent. More recent prospective observational studies and a meta-analysis of these studies found the magnitude of the association between homocysteine and cardiovascular risk to be lower. After adjustment for known cardiovascular risk factors and regression dilution bias, a 25 percent decrease in the homocysteine level (about 3 μmol per liter [0.4 mg per liter]) was associated with an 11 percent decrease in the risk of coronary heart disease and a 19 percent decrease in the risk of stroke.8 Our findings cannot definitively exclude the possibility that B vitamin supplements have a very small beneficial effect on coronary heart disease, of a magnitude similar to these more recent estimates of the strength of the epidemiologic association (for example, a reduction in risk of 10 percent or less). However, this appears unlikely, considering the consistency of our findings across various coronary heart disease outcomes and subgroups, the lack of effect of treatment on total ischemic events — for which the trial was well powered to detect even a 13 percent reduction in risk — and the concordant findings of the NORVIT and VISP trials. The apparent increase in the rate of unstable angina in the active-treatment group is inconsistent with the neutral findings for all other coronary heart disease outcomes evaluated and may be related to the difficulty in establishing this diagnosis and to the play of chance.
With regard to the risk of stroke, we observed an absolute reduction of 1.3 percentage points and a relative reduction of 24 percent among patients assigned to the active-treatment group. However, these results must be interpreted with caution. The number of strokes in our study was much lower than the number of coronary events, the confidence intervals around the estimated risk reduction are wide, and the results are not adjusted for the multiplicity of outcomes compared. Also, we found no effect of treatment on transient ischemic attacks. From a biologic perspective, a treatment benefit restricted to stroke would be difficult to explain. Furthermore, the two other large trials of homocysteine-lowering vitamins that have been completed did not show a beneficial effect of treatment on stroke.13,14 Therefore, we believe that the apparent beneficial effect of B vitamin supplements on stroke in our trial may represent either an overestimate of the real effect or a spurious result due to the play of chance. Ongoing trials and a meta-analysis of all homocysteine-lowering trials16 should be able to clarify this issue.
The discordance between the epidemiology of homocysteine and the results of the clinical trials completed to date is similar to that noted for antioxidant vitamins17 and estrogen18 and may be related to inherent limitations of observational studies. Indeed, homocysteine levels are related to renal dysfunction, smoking, elevated blood pressure, and other cardiovascular risk factors and are higher in people with atherosclerosis than in those without.4 Therefore, homocysteine could be a marker, but not a cause, of vascular disease, and the epidemiologic data could be the result of residual confounding that cannot be fully adjusted for, of reverse causality, or of both. Our findings may also relate to exposure to folate-fortified food in over 70 percent of the study patients. This exposure probably reduced the number of patients with substantially increased homocysteine levels, the subgroup that might be most likely to benefit from B vitamin supplementation. Several large trials are further exploring these questions.16
In conclusion, combined daily administration of 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 for five years had no beneficial effects on major vascular events in a high-risk population with vascular disease. Our results do not support the use of folic acid and B vitamin supplements as a preventive treatment.
Supported by a Canadian Institutes of Health Research Grant (MT-15418) and in-kind contributions by Jamieson Laboratories, Canada.
No potential conflict of interest relevant to this article was reported.
This article was published at www.nejm.org on March 12, 2006.
Source Information
The Writing Group (Eva Lonn, M.D., and Salim Yusuf, D.Phil., M.B., B.S., Population Health Research Institute, McMaster University, and the Department of Medicine, Division of Cardiology, Hamilton Health Sciences, Hamilton, Ont.; Malcolm J. Arnold, M.D., Department of Medicine, Division of Cardiology, University of Western Ontario, London; Patrick Sheridan, M.Sc., Janice Pogue, M.Sc., and Mary Micks, C.T.R.C., Population Health Research Institute, McMaster University, Hamilton, Ont.; Matthew J. McQueen, M.D., Ph.D., Pathology and Molecular Medicine, McMaster University, Hamilton, Ont.; Jeffrey Probstfield, M.D., University of Washington School of Medicine, Seattle; George Fodor, M.D., Ph.D., University of Ottawa Heart Institute, Ottawa; Claes Held, M.D., Ph.D., Department of Cardiology, Karolinska University Hospital, Stockholm; and Jacques Genest, Jr., M.D., Division of Cardiology, McGill University Health Center and Royal Victoria Hospital, Montreal) assumes responsibility for the overall content and integrity of the manuscript.
Address reprint requests to Dr. Lonn at the Population Health Research Institute, Hamilton General Hospital, 237 Barton St. East, Hamilton, ON L8L 2X2, Canada, or at lonnem@mcmaster.ca.
The HOPE-2 investigators are listed in the Appendix.
Appendix
The following persons participated in the HOPE-2 Study: Writing Group: — E. Lonn, S. Yusuf, M.J.O. Arnold, P. Sheridan, M.J. McQueen, J. Pogue, J. Probstfield, G. Fodor, C. Held, M. Micks, J. Genest, Jr.; Steering Committee — E. Lonn (chair and principal investigator), S. Yusuf (cochair), J. Genest, Jr. (coprincipal investigator); M.J.O. Arnold, A. Avezum, J. Bosch, J. Choy, G. Dagenais, R. Davies, M. Fisher, G. Fodor, T. Hamalainen, G. Heyndrickx, R. Hoeschen, W. Klein, R. Kuritzky, J. Mann, M. McQueen, M. Micks, B. Mitchell, J. Ostergren, L. Piegas, J. Pogue, J. Probstfield, P. Sleight, G. Spinas, B. Sussex, K. Teo, L. Title, R. Tsuyuki; Events Adjudication Committee — M.J.O. Arnold (chair), A. Arnold, P. Auger, A. Avezum, I. Bata, V. Bernstein, M. Bourassa, G. Dagenais, M. Fisher, G. Fodor, J. Grover, C. Held, R. Hoeschen, J. Mann, J. Mathew, D. Meldrum, C. Pilon, R. Roccaforte, C. Ross, R. Starra, B. Sussex, K. Teo; Substudies and Publication-Policy Committee — J. Probstfield (chair), R. Davies, E. Lonn, M. McQueen, J. Ostergren, S. Yusuf; Data and Safety Monitoring Board — D. Sackett (chair), R. Collins, E. Davis, C. Furberg, C. Hennekens, B. Pitt, W. Taylor; Senior Study Statistician — J. Pogue; Junior Study Statistician — P. Sheridan; Study Coordination — A. Avezum, J. Bosch, B. Cracknell, M. Fuentes, E. Lonn, C. MacKay, M. McQueen, M. Micks, L. Piegas, J. Pogue, L. Richardson, J. Riley, L. Sardo, P. Sheridan, M. Villamarin, W. West, S. Yuki Miyakoshi, S. Yusuf; Principal Investigators and Coinvestigators — Austria: M. Grisold, W. Klein; Belgium: G. Heyndrickx, Brazil: E. Alexandre, C. Amodeo, D. Araújo, D. Armaganijan, H. Barbato, M. Bertolami, L.C. Bodanese, F. Borelli, C.O.I. Brasil, A. Carvalho, S.M. Carvalhaes, A. Chaves, J.M. Esteves, M.Z. Fichino, B. Garbelini, N. Ghorayeb, G. Greque, C.P. Jaeger, F. Malheiros, V. Mozetic, F.S. Neto, O. Passarelli, A.C. Silva, P. Smith, A.G. Sousa, L.F. Tanajura, J. Tavares, M.N. de Villalon, H. Zatz; Canada: G. Abraham, N. Aris-Jilwan, M. Arnold, T. Ashton, P. Auger, M. Baird, T. Baitz, I. Bata, A. Belanger, V. Bernstein, R. Bessoudo, W. Bishop, P. Bogaty, M. Boulianne, R. Brossoit, W. Cameron, J. Campeau, S. Carrier, N. Chan, Y. Chan, J.-L. Chiasson, J. Choy, M. Crowther, B. Cujec, G. D'Amours, R.A. Davies, R.F. Davies, K.G. Dawson, F. Delage, G. DeRose, P. DeYoung, D. Dion, R. Dong, J. Douketis, M. Drobac, J. Dufton, R. Dupuis, A. Edwards, L. Finkelstein, T. Forbes, R. Fowlis, J. Frohlich, J. Fulop, R. Geddis, P. Gervais, S. Ghosh, P. Giannoccaro, R. Giroux, P. Gladstone, A. Glanz, E. Goode, D. Gossard, G. Gosselin, G. Goulet, P. Greenwood, F. Grondin, N. Habib, J. Halle, K. Harris, J. Heath, M. Heule, L. Higginson, B. Hoeschen, R. Houlden, I.M. Hramiak, J. Imrie, A. Irving, C.O. Jenkins, D. Johnstone, C. Joyce, N. Kandalaft, S. Kassam, A. Kenshole, H. Kim, J. Kornder, W.J. Kostuk, G. Kumar, R. Kuritzky, G. Kuruvilla, K. Kwok, Z. Lakhani, A. Lamy, C. Lauzon, M. LeBlanc, H. Lee, M. Lee, B. Lent, R. Lesoway, R. Loisel, E. Lonn, P. Ma, T. Machel, K. MacLellan, D. MacRitchie, S. Majumdar, D. Massel, T. Mathew, P. Mehta, D. Meldrum, A. Miller, F. Miller, J. Misterski, L.B. Mitchell, A. Montgomery, T. Muzyka, S. Nawaz, D. O'Keefe, G. Ong, S. Pallie, A. Panju, M.A. Patel, A. Pearce, P. Pflugfelder, C. Pilon, P. Plourde, C. Poirier, P. Polasek, G. Pruneau, S. Rabkin, M. Ravalia, T. Rebane, J. Ricci, C. Riel, M. Ruel, D. Saulnier, D. Savard, M. Sayeed, A. Selby, F. Sestier, W. Sheridan, G. Sherman, M. Shirley, G. Simkus, N. Singh, R. Smith, R. Southern, D. Spence, R. Starra, D. Steeves, L. Sternberg, R. St.-Hilaire, J. Stone, H. Sullivan, H. Sullivan, M. Sullivan, B. Sussex, J. Swan, T. Talibi, P. Tan, P. Tanser, D. Taylor, K. Teo, G. Thomasse, L. Title, W. Tymchak, T. Vakani, S. Vederah, R. Vexler, K. Wagner, M. Walker, A. Weeks, S. Wetmore, G. Wisenberg, M. Wolfe, K. Woo, B. Zinman; Denmark: H. Juhl, Finland: T. Hämäläinen; Germany: S. Cilaci, B. Friederichs, A. Gordalla, R. Hampel, A. Knauerhase, J. Mann, J. Maus, B. Mayinger, S. Miedlich, K. Miehle, S. Mühldorfer, H.P. Nast, R. Paschke, B. Prehn, R. Riel, V. Tirneci; the Netherlands: L.G. van Doorn; Slovak Republic: M. Kotrec, V. Krpciar, J. Lietava; Spain: X. Albert, R. Masiá, A. Karoni, I. Garcia Polo, C. Suárez; Sweden: M. Bennermo, H. Björkman, U.-B. Ericsson, C. Held, P. Katzman, U. Rosenqvist, K.A. Svensson; Switzerland: P. Gerber, T. Moccetti, E. Safwan, G. Spinas; United States: J. Abrams, S. Advani, A. Basu, S. Berger, G. Cohen, K. Danisa, M. Davidson, A. Dimova, C. Forchetti, L. Gage, J. Geohas, J. Gorham, S. Graham, S. Gupta, V. Hart, B. Hoogwerf, L. Horwitz, R. Kohn, E. Lader, R. Mack, D. Parikh, G. Pierpont, R.K. Primm, J. Probstfield, A. Rashkow, P. Reiter, R. Rough, K. Schwartz, V. Sridharan, A. Suryaprasad, A. Susmano, W. Wickemeyer, R. Zolty.
- References
References
1
Welch GN ,Loscalzo J . Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-1050
Full Text | Web of Science | Medline2
Harker LA ,Harlan JM ,Ross R . Effect of sulfinpyrazone on homocysteineinduced endothelial injury and arteriosclerosis in baboons. Circ Res 1983;53:731-739
Web of Science | Medline3
Harker LA ,Slichter SJ ,Scott CR ,Ross R . Homocysteinemia: vascular injury and arterial thrombosis. N Engl J Med 1974;291:537-543
Full Text | Web of Science | Medline4
Eikelboom JW ,Lonn E ,Genest J Jr ,Hankey G ,Yusuf S . Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999;131:363-375
Web of Science | Medline5
Boushey CJ ,Beresford SA ,Omenn GS ,Motulsky AG . A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-1057
CrossRef | Web of Science | Medline6
Wald DS ,Law M ,Morris JK . Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202-1202
CrossRef | Web of Science | Medline7
Klerk M ,Verhoef P ,Clarke R ,Blom HJ ,Kok FJ ,Schouten EG . MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002;288:2023-2031
CrossRef | Web of Science | Medline8
The Homocysteine Studies Collaboration
CrossRef | Web of Science9
Homocysteine Lowering Trialists' Collaboration
Web of Science | Medline10
Malinow MR ,Bostom AG ,Krauss RM . Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999;99:178-182
Web of Science | Medline11
Lonn E ,Held C ,Arnol JM , et al. Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial. Can J Cardiol 2006;22:47-53
CrossRef | Web of Science | Medline12
Alpert JS ,Thygesen K ,Antman E ,Bassand JP . Myocardial infarction redefined -- a consensus document of the joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-969[Erratum, J Am Coll Cardiol 2001;37:973.]
CrossRef | Web of Science | Medline13
Bonaa KH ,Njolstad I ,Ueland PM , et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-1588
Full Text | Web of Science | Medline14
Toole JF ,Malinow MR ,Chambless LE , et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-575
CrossRef | Web of Science | Medline15
Liem A ,Reynierse-Buitenwerf GH ,Zwinderman AH ,Jukema JW ,van Veldhuisen DJ . Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol 2003;41:2105-2113
CrossRef | Web of Science | Medline16
B-Vitamin Treatment Trialists' Collaboration
CrossRef | Web of Science | Medline17
Vivekananthan DP ,Penn MS ,Sapp SK ,Hsu A ,Topol EJ . Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003;361:2017-2023[Erratum, Lancet 2004;363:662.]
CrossRef | Web of Science | Medline18
Hulley S ,Grady D ,Bush T , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-613
CrossRef | Web of Science | Medline
- Citing Articles (391)
Citing Articles
1
Siamak Bidel, Jaakko Tuomilehto. 2012. Coffee and Cardiovascular Diseases. , 181-195.
CrossRef2
James House, Mingyan Jing, Sun-Young Hwang, Karmin O. 2012. Folic Acid and Pathogenesis of Cardiovascular Disease. , 95-110.
CrossRef3
Yong-Jun Wang, Su-Ming Zhang, Liqun Zhang, Chun-Xue Wang. (2012) Chinese Guidelines for the Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack 2010. CNS Neuroscience & Therapeutics 18:2, 93-101
CrossRef4
Graeme J Hankey. (2012) Nutrition and the risk of stroke. The Lancet Neurology 11:1, 66-81
CrossRef5
Tsung O. Cheng. (2012) Cardiovascular health, risks and diseases in contemporary China. International Journal of Cardiology 154:2, 233-242
CrossRef6
Helene McNulty, J. J. Strain, Kristina Pentieva, Mary Ward. (2011) C1 metabolism and CVD outcomes in older adults. Proceedings of the Nutrition Society1-9
CrossRef7
C.-S. Kim, Y.-R. Kim, A. Naqvi, S. Kumar, T. A. Hoffman, S.-B. Jung, A. Kumar, B.-H. Jeon, D. M. McNamara, K. Irani. (2011) Homocysteine promotes human endothelial cell dysfunction via site-specific epigenetic regulation of p66shc. Cardiovascular Research 92:3, 466-475
CrossRef8
Julio A. Carbayo Herencia. (2011) Nuevos marcadores de riesgo cardiovascular. ¿Pueden influir en la clasificación del riesgo cardiovascular?. Clínica e Investigación en Arteriosclerosis
CrossRef9
B. Zappacosta, S. Persichilli, L. Iacoviello, A. Di Castelnuovo, M. Graziano, J. Gervasoni, E. Leoncini, G. Cimino, P. Mastroiacovo. (2011) Folate, vitamin B12 and homocysteine status in an Italian blood donor population. Nutrition, Metabolism and Cardiovascular Diseases
CrossRef10
D. Monneret, R. Tamisier, V. Ducros, C. Garrel, P. Levy, J.P. Baguet, P. Faure, J.L. Pépin. (2011) The impact of obstructive sleep apnea on homocysteine and carotid remodeling in metabolic syndrome. Respiratory Physiology & Neurobiology
CrossRef11
K M A Swart, N M van Schoor, H J Blom, Y M Smulders, P Lips. (2011) Homocysteine and the risk of nursing home admission and mortality in older persons. European Journal of Clinical Nutrition
CrossRef12
Judith P. Rooks. (2011) Safety and Risks of Nitrous Oxide Labor Analgesia: A Review. Journal of Midwifery & Women's Health 56:6, 557-565
CrossRef13
Tsung O. Cheng. (2011) Cardiovascular health, risks and diseases in contemporary China. International Journal of Cardiology 152:3, 285-294
CrossRef14
Antonysunil Adaikalakoteswari, Naila Rabbani, Sarwono Waspadji, Askandar Tjokroprawiro, Sri H.K.S. Kariadi, John M.F. Adam, Paul J. Thornalley. (2011) Disturbance of B-vitamin status in people with type 2 diabetes in Indonesia—Link to renal status, glycemic control and vascular inflammation. Diabetes Research and Clinical Practice
CrossRef15
Jessica A. Sipkens, Nynke Hahn, Carlien S. den Brand, Christof Meischl, Saskia A. G. M. Cillessen, Desirée E. C. Smith, Lynda J. M. Juffermans, René J. P. Musters, Dirk Roos, Cornelis Jakobs, Henk J. Blom, Yvo M. Smulders, Paul A. J. Krijnen, Coen D. A. Stehouwer, Jan A. Rauwerda, Victor W. M. Hinsbergh, Hans W. M. Niessen. (2011) Homocysteine-Induced Apoptosis in Endothelial Cells Coincides With Nuclear NOX2 and Peri-nuclear NOX4 Activity. Cell Biochemistry and Biophysics
CrossRef16
M. Studer, A. Barbaud, F. Truchetet, P.-L. N’guyen, A.-C. Bursztejn, J.-L. Schmutz. (2011) Hyperhomocystéinémie et ulcères de jambes : étude prospective de 68 observations. Annales de Dermatologie et de Vénéréologie 138:10, 645-651
CrossRef17
D. Papaioannou, K. L. Cooper, C. Carroll, D. Hind, H. Squires, P. Tappenden, R. F. Logan. (2011) Antioxidants in the chemoprevention of colorectal cancer and colorectal adenomas in the general population: a systematic review and meta-analysis. Colorectal Disease 13:10, 1085-1099
CrossRef18
Julia A.M. Anderson, Jeffrey I. Weitz. (2011) Hypercoagulable States. Critical Care Clinics 27:4, 933-952
CrossRef19
Joseph E. Baggott, Robert A. Oster, Tsunenobu Tamura. (2011) Meta-analysis of cancer risk in folic acid supplementation trials. Cancer Epidemiology
CrossRef20
Dan Feng, Yan Zhou, Min Xia, Jing Ma. (2011) Folic acid inhibits lipopolysaccharide-induced inflammatory response in RAW264.7 macrophages by suppressing MAPKs and NF-κB activation. Inflammation Research 60:9, 817-822
CrossRef21
Johan Hultdin, Bethany Van Guelpen, Anna Winkvist, Göran Hallmans, Lars Weinehall, Birgitta Stegmayr, Torbjörn K. Nilsson. (2011) Prospective study of first stroke in relation to plasma homocysteine and MTHFR 677C>T and 1298A>C genotypes and haplotypes – evidence for an association with hemorrhagic stroke. Clinical Chemistry and Laboratory Medicine 49:9, 1555-1562
CrossRef22
B. Fuentes, J. Gallego, A. Gil-Nuñez, A. Morales, F. Purroy, J. Roquer, T. Segura, J. Tejada, A. Lago, E. Díez-Tejedor. (2011) Guía para el tratamiento preventivo del ictus isquémico y AIT (I). Actuación sobre los factores de riesgo y estilo de vida. Neurología
CrossRef23
Shi-Sheng Zhou, Yi-Ming Zhou, Da Li, Yong-Zhi Lun. (2011) Dietary methyl-consuming compounds and metabolic syndrome. Hypertension Research
CrossRef24
Amy K. Keating, Cynthia Freehauf, Hua Jiang, Gary L. Brodsky, Sally P. Stabler, Robert H. Allen, Douglas K. Graham, Janet A. Thomas, Johan L.K. Van Hove, Kenneth N. Maclean. (2011) Constitutive induction of pro-inflammatory and chemotactic cytokines in cystathionine beta-synthase deficient homocystinuria. Molecular Genetics and Metabolism 103:4, 330-337
CrossRef25
Michael V Holmes, Paul Newcombe, Jaroslav A Hubacek, Reecha Sofat, Sally L Ricketts, Jackie Cooper, Monique MB Breteler, Leonelo E Bautista, Pankaj Sharma, John C Whittaker, Liam Smeeth, F Gerald R Fowkes, Ale Algra, Veronika Shmeleva, Zoltan Szolnoki, Mark Roest, Michael Linnebank, Jeppe Zacho, Michael A Nalls, Andrew B Singleton, Luigi Ferrucci, John Hardy, Bradford B Worrall, Stephen S Rich, Mar Matarin, Paul E Norman, Leon Flicker, Osvaldo P Almeida, Frank M van Bockxmeer, Hiroshi Shimokata, Kay-Tee Khaw, Nicholas J Wareham, Martin Bobak, Jonathan AC Sterne, George Davey Smith, Philippa J Talmud, Cornelia van Duijn, Steve E Humphries, Jackie F Price, Shah Ebrahim, Debbie A Lawlor, Graeme J Hankey, James F Meschia, Manjinder S Sandhu, Aroon D Hingorani, Juan P Casas. (2011) Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. The Lancet 378:9791, 584-594
CrossRef26
Vikas Veeranna, Sandip K. Zalawadiya, Ashutosh Niraj, Jyotiranjan Pradhan, Brian Ference, Robert C. Burack, Sony Jacob, Luis Afonso. (2011) Homocysteine and Reclassification of Cardiovascular Disease Risk. Journal of the American College of Cardiology 58:10, 1025-1033
CrossRef27
Chris J. McNeil, John H. Beattie, M-J Gordon, Lynn P. Pirie, Susan J. Duthie. (2011) Differential effects of nutritional folic acid deficiency and moderate hyperhomocysteinemia on aortic plaque formation and genome-wide DNA methylation in vascular tissue from ApoE-/- mice. Clinical Epigenetics 2:2, 361-368
CrossRef28
Kerstin Wustmann, Marco Klaey, Annika Burow, Sidney G. Shaw, Otto M. Hess, Yves Allemann. (2011) Additive Effect of Homocysteine- and Cholesterol-Lowering Therapy on Endothelium-Dependent Vasodilation in Patients with Cardiovascular Disease. Cardiovascular Therapeuticsno-no
CrossRef29
Joel B. Mason. (2011) Unraveling the complex relationship between folate and cancer risk. BioFactors 37:4, 253-260
CrossRef30
Valentina Lotto, Sang-Woon Choi, Simonetta Friso. (2011) Vitamin B6: a challenging link between nutrition and inflammation in CVD. British Journal of Nutrition 106:02, 183-195
CrossRef31
D. Rosenberger, R. Gargoum, N. Tyagi, N. Metreveli, U. Sen, C. Maldonado, S. Tyagi. (2011) Homocysteine enriched diet leads to prolonged QT interval and reduced left ventricular performance in telemetric monitored mice. Nutrition, Metabolism and Cardiovascular Diseases 21:7, 492-498
CrossRef32
Federico Cacciapuoti. (2011) Hyper-homocysteinemia: a novel risk factor or a powerful marker for cardiovascular diseases? Pathogenetic and therapeutical uncertainties. Journal of Thrombosis and Thrombolysis 32:1, 82-88
CrossRef33
Bartosz T. Grobelny, Andrew F. Ducruet, Peter A. DeRosa, Ivan S. Kotchetkov, Brad E. Zacharia, Zachary L. Hickman, Luis Fernandez, Reshma Narula, Jan Claassen, Kiwon Lee, Neeraj Badjatia, Stephan A. Mayer, E. Sander Connolly. (2011) Gain-of-function polymorphisms of cystathionine β-synthase and delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage. Journal of Neurosurgery 115:1, 101-107
CrossRef34
Giuseppina Tiziana Russo, Antonino Di Benedetto, Domenico Magazzù, Annalisa Giandalia, Carlo Bruno Giorda, Riccardo Ientile, Marcello Previti, Enrico Di Cesare, Domenico Cucinotta. (2011) Mild hyperhomocysteinemia, C677T polymorphism on methylenetetrahydrofolate reductase gene and the risk of macroangiopathy in type 2 diabetes: a prospective study. Acta Diabetologica 48:2, 95-101
CrossRef35
T. Kwok, J. Lee, C.B. Law, P.C. Pan, C.Y. Yung, K.C. Choi, L.C. Lam. (2011) A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people. Clinical Nutrition 30:3, 297-302
CrossRef36
Peter Libby, Paul M Ridker, Göran K. Hansson. (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473:7347, 317-325
CrossRef37
K. Kuśmierek, G. Chwatko, R. Głowacki, P. Kubalczyk, E. Bald. (2011) Ultraviolet derivatization of low-molecular-mass thiols for high performance liquid chromatography and capillary electrophoresis analysis. Journal of Chromatography B 879:17-18, 1290-1307
CrossRef38
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 57:19, e215-e367
CrossRef39
Christos Lioupis, Calypso Barbatis, Aggeliki Drougou, Vasiliki Koliaraki, Avgi Mamalaki, Christos Klonaris, Sotirios Georgopoulos, Vasilios Andrikopoulos, Elias Bastounis. (2011) Association of haptoglobin genotype and common cardiovascular risk factors with the amount of iron in atherosclerotic carotid plaques. Atherosclerosis 216:1, 131-138
CrossRef40
Kaustubh C. Dabhadkar, Ambar Kulshreshtha, Mohammed K. Ali, K.M. Venkat Narayan. (2011) Prospects for a Cardiovascular Disease Prevention Polypill. Annual Review of Public Health 32:1, 23-38
CrossRef41
Zhiting Jiang, Jingbo Sun, Qionglin Liang, Yefeng Cai, Shasha Li, Yan Huang, Yiming Wang, Guoan Luo. (2011) A metabonomic approach applied to predict patients with cerebral infarction. Talanta 84:2, 298-304
CrossRef42
Federico Cacciapuoti. (2011) Some considerations about the hypercoagulable states and their treatments. Blood Coagulation & Fibrinolysis 22:3, 155-159
CrossRef43
Richard Walden, Brian Tomlinson. 2011. Cardiovascular Disease. , 333-359.
CrossRef44
Kenji Okumura, Hideto Tsukamoto. (2011) Folate in smokers. Clinica Chimica Acta 412:7-8, 521-526
CrossRef45
Dimitri E. Zylberstein, Lauren Lissner, Cecilia Björkelund, Kirsten Mehlig, Dag S. Thelle, Deborah Gustafson, Svante Östling, Margda Waern, Xinxin Guo, Ingmar Skoog. (2011) Midlife homocysteine and late-life dementia in women. A prospective population study. Neurobiology of Aging 32:3, 380-386
CrossRef46
M. Endres, P. U. Heuschmann, U. Laufs, A. M. Hakim. (2011) Primary prevention of stroke: blood pressure, lipids, and heart failure. European Heart Journal 32:5, 545-552
CrossRef47
Balazs Debreceni, Laszlo Debreceni. (2011) Why Do Homocysteine-Lowering B Vitamin and Antioxidant E Vitamin Supplementations Appear To Be Ineffective in the Prevention of Cardiovascular Diseases?. Cardiovascular Therapeuticsno-no
CrossRef48
Lisa A. D’Agostino, Karen P. Lam, Richard Lee, Philip Britz-McKibbin. (2011) Comprehensive Plasma Thiol Redox Status Determination for Metabolomics. Journal of Proteome Research 10:2, 592-603
CrossRef49
J. Fife, S. Raniga, P. N. Hider, F. A. Frizelle. (2011) Folic acid supplementation and colorectal cancer risk: a meta-analysis. Colorectal Disease 13:2, 132-137
CrossRef50
Susan J. Duthie. (2011) Epigenetic modifications and human pathologies: cancer and CVD. Proceedings of the Nutrition Society 70:01, 47-56
CrossRef51
Harold P. Adams. (2011) Failure of Vitamin Supplementation to Lower the Risk of Recurrent Stroke. Current Neurology and Neuroscience Reports 11:1, 1-5
CrossRef52
Robert Clarke, Jim Halsey, Derrick Bennett, Sarah Lewington. (2011) Homocysteine and vascular disease: review of published results of the homocysteine-lowering trials. Journal of Inherited Metabolic Disease 34:1, 83-91
CrossRef53
Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John D. Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan B. Fowler, Gary Friday, Vicki S. Hertzberg, E. Bruce McIff, Wesley S. Moore, Peter D. Panagos, Thomas S. Riles, Robert H. Rosenwasser, Allen J. Taylor. (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease. Journal of the American College of Cardiology 57:8, e16-e94
CrossRef54
Rosa Maria Guéant-Rodriguez, Rosario Spada, Maira Moreno-Garcia, Guido Anello, Paolo Bosco, Laurent Lagrost, Antonino Romano, Maurizio Elia, Jean-Louis Guéant. (2011) Homocysteine is a determinant of ApoA-I and both are associated with ankle brachial index, in an Ambulatory Elderly Population. Atherosclerosis 214:2, 480-485
CrossRef55
Ana C.M. Aléssio, Célio X.C. Santos, Victor Debbas, Laurione C. Oliveira, Renato Haddad, Joyce M. Annichino-Bizzacchi. (2011) Evaluation of mild hyperhomocysteinemia during the development of atherosclerosis in apolipoprotein E-deficient and normal mice. Experimental and Molecular Pathology 90:1, 45-50
CrossRef56
Dan Farbstein, Yitzchak Z. Soloveichik, Nina S. Levy, Andrew P. Levy. (2011) Genetics of Redox Systems and Their Relationship with Cardiovascular Disease. Current Atherosclerosis Reports
CrossRef57
Jaseong Koo. (2011) Vitamins for Stroke Prevention. Korean Journal of Stroke 13:2, 49
CrossRef58
A. W. M. Janssen, F. E. Leeuw, M. C. H. Janssen. (2011) Risk factors for ischemic stroke and transient ischemic attack in patients under age 50. Journal of Thrombosis and Thrombolysis 31:1, 85-91
CrossRef59
Yasue Uchida, Saiko Sugiura, Fujiko Ando, Tsutomu Nakashima, Hiroshi Shimokata. (2011) Hearing impairment risk and interaction of folate metabolism related gene polymorphisms in an aging study. BMC Medical Genetics 12:1, 35
CrossRef60
Ioana Cotlarciuc, Toby Andrew, Tracy Dew, Gail Clement, Raj Gill, Gabriela Surdulescu, Roy Sherwood, Kourosh R. Ahmadi. (2011) The Basis of Differential Responses to Folic Acid Supplementation. Journal of Nutrigenetics and Nutrigenomics 4:2, 99-109
CrossRef61
Maria Marino, Roberta Masella, Pamela Bulzomi, Ilaria Campesi, Walter Malorni, Flavia Franconi. (2011) Nutrition and human health from a sex–gender perspective. Molecular Aspects of Medicine
CrossRef62
Hee-Won Moon, Dong Hee Whang, Young Jin Ko, Shin Young Joo, Yeo-Min Yun, Mina Hur, Jin Q Kim. (2011) Reference interval and determinants of the serum homocysteine level in a Korean population. Journal of Clinical Laboratory Analysis 25:5, 317-323
CrossRef63
(2011) Nihon Toseki Igakkai Zasshi 44:5, 353-357
CrossRef64
Peter Laszlo Lakatos, Lajos S. Kiss, Pal Miheller. (2011) Nutritional Influences in Selected Gastrointestinal Diseases. Digestive Diseases 29:2, 154-165
CrossRef65
Edward G Lynn, Richard C Austin. (2011) Hydrogen sulfide in the pathogenesis of atherosclerosis and its therapeutic potential. Expert Review of Clinical Pharmacology 4:1, 97-108
CrossRef66
Scott E. Kasner, Brett L. Cucchiara. 2011. Treatment of “Other” Stroke Etiologies. , 1084-1105.
CrossRef67
Ingrid Avalos, C. Michael Stein. 2011. Atherosclerosis and Tissue Injury in Systemic Lupus Erythematosus. , 513-522.
CrossRef68
Julia A.M. Anderson, Jeffrey I. Weitz. (2010) Hypercoagulable States. Clinics in Chest Medicine 31:4, 659-673
CrossRef69
2010. Further Reading. , 378-407.
CrossRef70
Guixiang Zhao, Earl S Ford, Chaoyang Li, Ali H Mokdad. (2010) The prevalence and correlates of taking folic acid and vitamin supplements among adults aged ≥45 years with CVD. Public Health Nutrition 13:11, 1810-1817
CrossRef71
Amytis Towfighi, Daniela Markovic, Bruce Ovbiagele. (2010) Pronounced association of elevated serum homocysteine with stroke in subgroups of individuals: A nationwide study. Journal of the Neurological Sciences 298:1-2, 153-157
CrossRef72
C. A. M. Anderson, S. H. Jee, J. Charleston, M. Narrett, L. J. Appel. (2010) Effects of Folic Acid Supplementation on Serum Folate and Plasma Homocysteine Concentrations in Older Adults: A Dose-Response Trial. American Journal of Epidemiology 172:8, 932-941
CrossRef73
2010. Role of Micronutrients in the Prevention of Coronary Artery Disease and Improvement of the Standard Therapy. , 55-76.
CrossRef74
Jim I. Mann. (2010) Evidence-based nutrition: Does it differ from evidence-based medicine?. Annals of Medicine 42:7, 475-486
CrossRef75
M. Ebbing, K. H. Bønaa, E. Arnesen, P. M. Ueland, J. E. Nordrehaug, K. Rasmussen, I. Njølstad, D. W. Nilsen, H. Refsum, A. Tverdal, S. E. Vollset, H. Schirmer, Ø. Bleie, T. Steigen, Ø. Midttun, Å. Fredriksen, E. R. Pedersen, O. Nygård. (2010) Combined analyses and extended follow-up of two randomized controlled homocysteine-lowering B-vitamin trials. Journal of Internal Medicine 268:4, 367-382
CrossRef76
Katalin Fekete, Cristiana Berti, Irene Cetin, Maria Hermoso, Berthold V. Koletzko, Tamás Decsi. (2010) Perinatal folate supply: relevance in health outcome parameters. Maternal & Child Nutrition 6, 23-38
CrossRef77
Osvaldo P. Almeida, Kylie Marsh, Helman Alfonso, Leon Flicker, Timothy M.E. Davis, Graeme J. Hankey. (2010) B-vitamins reduce the long-term risk of depression after stroke: The VITATOPS-DEP trial. Annals of Neurology 68:4, 503-510
CrossRef78
Rui-xue Yang, Shan-ying Huang, Fang-fang Yan, Xiao-ting Lu, Yi-fan Xing, Yan Liu, Yun-fang Liu, Yu-xia Zhao. (2010) Danshensu protects vascular endothelia in a rat model of hyperhomocysteinemia. Acta Pharmacologica Sinica 31:10, 1395-1400
CrossRef79
Lonneke M. L. De Lau, Frank W. G. Leebeek, Moniek P. M. De Maat, Peter J. Koudstaal, Diederik W. J. Dippel. (2010) Reviews: A review of hereditary and acquired coagulation disorders in the aetiology of ischaemic stroke. International Journal of Stroke 5:5, 385-394
CrossRef80
Constantina Papoutsakis, Yannis Manios, Faidon Magkos, Evaggelos Papaconstantinou, Kleopatra H. Schulpis, Antonis Zampelas, Antonia L. Matalas, Nikos Yiannakouris. (2010) Effect of the methylenetetrahydrofolate reductase (MTHFR 677C>T) polymorphism on plasma homocysteine concentrations in healthy children is influenced by consumption of folate-fortified foods. Nutrition 26:10, 969-974
CrossRef81
Sadik Acikel, Mehmet Dogan, Ramazan Akdemir. (2010) Homocysteine-lowering therapy for preventing atherothrombotic events: Its role in high risk population. International Journal of Cardiology 144:2, 326-328
CrossRef82
Jiangtao Yan, James K. Liao, Daowen Wang. (2010) Elevated homocysteine and C-reactive protein levels independently predict worsening prognosis after stroke in Chinese patients. Journal of Huazhong University of Science and Technology [Medical Sciences] 30:5, 643-647
CrossRef83
Ulrich Laufs, Uta C. Hoppe, Stephan Rosenkranz, Paulus Kirchhof, Michael Böhm, Hans-Christoph Diener, Matthias Endres, Martin Grond, Werner Hacke, Thomas Meinertz, E. Bernd Ringelstein, Joachim Röther, Martin Dichgans. (2010) Cardiological evaluation after cerebral ischaemia. Clinical Research in Cardiology 99:10, 609-625
CrossRef84
John H. Block. 2010. Vitamins. .
CrossRef85
Paul J. Thornalley, Naila Rabbani. (2010) Therapy: Vitamin B6, B9 and B12 in diabetic nephropathy—beware. Nature Reviews Endocrinology 6:9, 477-478
CrossRef86
June Leung, Brett Larive, Johanna Dwyer, Patricia Hibberd, Paul Jacques, William Rand. (2010) Folic Acid Supplementation and Cardiac and Stroke Mortality among Hemodialysis Patients. Journal of Renal Nutrition 20:5, 293-302
CrossRef87
J. David Spence. (2010) Secondary stroke prevention. Nature Reviews Neurology
CrossRef88
Koon K. Teo, Yan Liang. (2010) Polypill: Lights and Shadows. Current Hypertension Reports 12:4, 276-281
CrossRef89
I Johansson, B Van Guelpen, J Hultdin, M Johansson, G Hallmans, P Stattin. (2010) Validity of food frequency questionnaire estimated intakes of folate and other B vitamins in a region without folic acid fortification. European Journal of Clinical Nutrition 64:8, 905-913
CrossRef90
Nicole M. Wolf, Kristin Mueller, Frank Hirche, Erika Most, Josef Pallauf, Andreas S. Mueller. (2010) Study of molecular targets influencing homocysteine and cholesterol metabolism in growing rats by manipulation of dietary selenium and methionine concentrations. British Journal of Nutrition 104:04, 520-532
CrossRef91
Clarie B. Hollenbeck. (2010) The Importance of Being Choline. Journal of the American Dietetic Association 110:8, 1162-1165
CrossRef92
Lonneke ML de Lau, Frank WG Leebeek, Moniek PM de Maat, Peter J Koudstaal, Diederik WJ Dippel. (2010) Screening for coagulation disorders in patients with ischemic stroke. Expert Review of Neurotherapeutics 10:8, 1321-1329
CrossRef93
Edgar R. Miller, Stephen Juraschek, Roberto Pastor-Barriuso, Lydia A. Bazzano, Lawrence J. Appel, Eliseo Guallar. (2010) Meta-Analysis of Folic Acid Supplementation Trials on Risk of Cardiovascular Disease and Risk Interaction With Baseline Homocysteine Levels. The American Journal of Cardiology 106:4, 517-527
CrossRef94
Erika Coria-Ramirez, Leopoldo Nieto Cisneros, Sandra Treviño-Perez, Isabel Ibarra-Gonzalez, Jesus Casillas-Rodriguez, Abraham Majluf-Cruz. (2010) Effect of Highly Active Antiretroviral Therapy on Homocysteine Plasma Concentrations in HIV-1–Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 54:5, 477-481
CrossRef95
Santiago Garcia, Sara T.N. Murray, Thomas E. Moritz, Gordon Pierpont, Steven Goldman, Greg C. Larsen, Fred Littooy, Herbert B. Ward, Edward O. McFalls. (2010) Les lésions coronaires symptomatiques exigeant une intervention coronaire percutanée après chirurgie vasculaire se compliquent souvent de resténoses intra-stents dans les stent nus. Annales de Chirurgie Vasculaire 24:5, 651-656
CrossRef96
L. K. Rao, A. M. Francis, U. Wilcox, J. P. Miller, P. Nagele. (2010) Pre-operative vitamin B infusion and prevention of nitrous oxide-induced homocysteine increase. Anaesthesia 65:7, 710-715
CrossRef97
Ramazan Kurt, Yusuf Yilmaz, Fatih Ermis, Sevgi Kalayoglu Besisik, Nihat Polat, Ali Elitok, Huseyin Oflaz, Mehmet Akif Karan. (2010) Folic Acid and Vitamin B12 Supplementation Improves Coronary Flow Reserve in Elderly Subjects with Vitamin B12 Deficiency. Archives of Medical Research 41:5, 369-372
CrossRef98
S. Eilat-Adar, U. Goldbourt. (2010) Nutritional recommendations for preventing coronary heart disease in women: Evidence concerning whole foods and supplements. Nutrition, Metabolism and Cardiovascular Diseases 20:6, 459-466
CrossRef99
Michael Lever, Sandy Slow. (2010) The clinical significance of betaine, an osmolyte with a key role in methyl group metabolism. Clinical Biochemistry 43:9, 732-744
CrossRef100
Katsushi Koyama, Akinori Ito, Jun Yamamoto, Takae Nishio, Junko Kajikuri, Yasuaki Dohi, Nobuyuki Ohte, Akira Sano, Hiroshi Nakamura, Hiromichi Kumagai, Takeo Itoh. (2010) Randomized Controlled Trial of the Effect of Short-term Coadministration of Methylcobalamin and Folate on Serum ADMA Concentration in Patients Receiving Long-term Hemodialysis. American Journal of Kidney Diseases 55:6, 1069-1078
CrossRef101
Akiko Imamura, Ryuichiro Murakami, Ryotaro Takahashi, Xian Wu Cheng, Yasushi Numaguchi, Toyoaki Murohara, Kenji Okumura. (2010) Low folate levels may be an atherogenic factor regardless of homocysteine levels in young healthy nonsmokers. Metabolism 59:5, 728-733
CrossRef102
John H. Block. 2010. Selective Toxicity. .
CrossRef103
Thomas F. Whayne, Jr. (2010) What Should Medical Practitioners Know about the Role of Alternative Medicines in Cardiovascular Disease Management?. Cardiovascular Therapeutics 28:2, 106-123
CrossRef104
U. Laufs, U.C. Hoppe, S. Rosenkranz, P. Kirchhof, M. Böhm, H.-C. Diener, M. Endres, M. Grond, W. Hacke, T. Meinertz, E.B. Ringelstein, J. Röther, M. Dichgans. (2010) Kardiologische Diagnostik nach zerebraler Ischämie. Der Nervenarzt 81:4, 444-462
CrossRef105
C. CARROLL, K. COOPER, D. PAPAIOANNOU, D. HIND, P. TAPPENDEN, H. PILGRIM, A. BOOTH. (2010) Meta-analysis: folic acid in the chemoprevention of colorectal adenomas and colorectal cancer. Alimentary Pharmacology & Therapeutics 31:7, 708-718
CrossRef106
John H. Page, Jing Ma, Stephanie E. Chiuve, Meir J. Stampfer, Jacob Selhub, JoAnn E. Manson, Eric B. Rimm. (2010) Plasma total cysteine and total homocysteine and risk of myocardial infarction in women: A prospective study. American Heart Journal 159:4, 599-604
CrossRef107
Bethany Guelpen, Anna M. Dahlin, Johan Hultdin, Vincy Eklöf, Ingegerd Johansson, Maria L. Henriksson, Inger Cullman, Göran Hallmans, Richard Palmqvist. (2010) One-carbon metabolism and CpG island methylator phenotype status in incident colorectal cancer: a nested case–referent study. Cancer Causes & Control 21:4, 557-566
CrossRef108
Nina Roswall. (2010) Folate and lung cancer risk. Lung Cancer 67:3, 380-381
CrossRef109
Geraldine Horigan, Helene McNulty, Mary Ward, JJ Strain, John Purvis, John M Scott. (2010) Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C→T polymorphism in MTHFR. Journal of Hypertension 28:3, 478-486
CrossRef110
Gwendolen Buhr, Connie W. Bales. (2010) Nutritional Supplements for Older Adults: Review and Recommendations—Part II. Journal of Nutrition For the Elderly 29:1, 42-71
CrossRef111
C. P. Wilson, H. McNulty, J. M. Scott, J. J. Strain, M. Ward. (2010) Postgraduate Symposium The MTHFR C677T polymorphism, B-vitamins and blood pressure. Proceedings of the Nutrition Society 69:01, 156
CrossRef112
Ai-Jun Liu, Jin-Min Guo, Weiliang Xia, Ding-Feng Su. (2010) New strategies for the prevention of stroke. Clinical and Experimental Pharmacology and Physiology 37:2, 265-271
CrossRef113
Weili Zhang, Kai Sun, Jinxing Chen, Yuhua Liao, Qin Qin, Aiqun Ma, Daowen Wang, Zhiming Zhu, Yibo Wang, Rutai Hui. (2010) High plasma homocysteine levels contribute to the risk of stroke recurrence and all-cause mortality in a large prospective stroke population. Clinical Science 118:3, 187-194
CrossRef114
Vincenzo Belcastro, Pasquale Striano, Gaetano Gorgone, Cinzia Costa, Clotilde Ciampa, Daniela Caccamo, Laura R. Pisani, Giancarla Oteri, Maria G. Marciani, Umberto Aguglia, Salvatore Striano, Riccardo Ientile, Paolo Calabresi, Francesco Pisani. (2010) Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs. Epilepsia 51:2, 274-279
CrossRef115
Tomohiro Osanai, Naoto Fujiwara, Satoko Sasaki, Norifumi Metoki, Genta Saitoh, Hirofumi Tomita, Takashi Nishimura, Shuji Shibutani, Hiroaki Yokoyama, Yoshiyuki Konta, Koji Magota, Ken Okumura. (2010) Novel pro-atherogenic molecule coupling factor 6 is elevated in patients with stroke: A possible linkage to homocysteine. Annals of Medicine 42:1, 79-86
CrossRef116
Simona Sacco, Antonio Carolei. (2010) Homocysteine and stroke: another brick in the wall. Clinical Science 118:3, 183-185
CrossRef117
Anders Hovland, Randolf Hardersen, Erik Waage Nielsen, Tom Eirik Mollnes, Knut Tore Lappegård. (2010) Hematologic and hemostatic changes induced by different columns during LDL apheresis. Journal of Clinical Apheresis 25:5, 294-300
CrossRef118
W. Mei, Y. Rong, L. Jinming, L. Yongjun, Z. Hui. (2010) Effect of homocysteine interventions on the risk of cardiocerebrovascular events: a meta-analysis of randomised controlled trials. International Journal of Clinical Practice 64:2, 208-215
CrossRef119
Hongseog Seo, Hyunhee Oh, Hyesoon Park, Miyoung Park, Yangsoo Jang, Myoungsook Lee. (2010) Contribution of Dietary Intakes of Antioxidants to Homocysteine-Induced Low Density Lipoprotein (LDL) Oxidation in Atherosclerotic Patients. Yonsei Medical Journal 51:4, 526
CrossRef120
Nigel D. Toussaint, Grahame J. Elder, Peter G. Kerr. (2010) A Rational Guide to Reducing Fracture Risk in Dialysis Patients. Seminars in Dialysis 23:1, 43-54
CrossRef121
Utpal Sen, Suresh C. Tyagi. (2010) Homocysteine and Hypertension in Diabetes: Does PPARγ Have a Regulatory Role?. PPAR Research 2010, 1-12
CrossRef122
Pawan D Patel, Rohit R Arora. (2010) Practical Implications of ACC/AHA 2007 Guidelines for the Management of Unstable Angina/Non-ST Elevation Myocardial Infarction. American Journal of Therapeutics 17:1, e24-e40
CrossRef123
Kelly T. Williams, Kevin L. Schalinske. (2010) Homocysteine metabolism and its relation to health and disease. BioFactorsNA-NA
CrossRef124
W. Atkinson, S. Slow, J. Elmslie, M. Lever, S.T. Chambers, P.M. George. (2009) Dietary and supplementary betaine: Effects on betaine and homocysteine concentrations in males. Nutrition, Metabolism and Cardiovascular Diseases 19:11, 767-773
CrossRef125
Kari Anne R. Tobin, Kirsten B. Holven, Kjetil Retterstøl, Ellen Strøm, Leiv Ose, Pål Aukrust, Marit S. Nenseter. (2009) Cystatin C levels in plasma and peripheral blood mononuclear cells among hyperhomocysteinaemic subjects: effect of treatment with B-vitamins. British Journal of Nutrition 102:12, 1783
CrossRef126
Eva Lonn, Salim Yusuf. (2009) Polypill: the evidence and the promise. Current Opinion in Lipidology 20:6, 453-459
CrossRef127
Ling Gao, Karel Chalupsky, Enrico Stefani, Hua Cai. (2009) Mechanistic insights into folic acid-dependent vascular protection: Dihydrofolate reductase (DHFR)-mediated reduction in oxidant stress in endothelial cells and angiotensin II-infused mice: A novel HPLC-based fluorescent assay for DHFR activity. Journal of Molecular and Cellular Cardiology 47:6, 752-760
CrossRef128
Sari Kalin, Eric Rimm. 2009. Folate and Vascular Disease. , 263-290.
CrossRef129
Dan Sato, Tomoyoshi Nozaki. (2009) Methionine gamma-lyase: The unique reaction mechanism, physiological roles, and therapeutic applications against infectious diseases and cancers. IUBMB Life 61:11, 1019-1028
CrossRef130
F.L. Fimognari, L. Loffredo, S. Di Simone, F. Sampietro, R. Pastorelli, M. Monaldo, F. Violi, A. D'Angelo. (2009) Hyperhomocysteinaemia and poor vitamin B status in chronic obstructive pulmonary disease. Nutrition, Metabolism and Cardiovascular Diseases 19:9, 654-659
CrossRef131
Karim Valji, Michael Linenberger. (2009) Chasing Clot: Thrombophilic States and the Interventionalist. Journal of Vascular and Interventional Radiology 20:11, 1403-1416
CrossRef132
Alexa Boer Kimball, Ying Wu. (2009) Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis. International Journal of Dermatology 48:11, 1147-1156
CrossRef133
Arturo J Martí-Carvajal, Ivan Solà, Dimitrios Lathyris, Georgia Salanti, Arturo J Martí-Carvajal. 2009. Homocysteine lowering interventions for preventing cardiovascular events. .
CrossRef134
Carlijn R. Hooijmans, Henk J. Blom, Dinny Oppenraaij-Emmerzaal, Merel Ritskes-Hoitinga, Amanda J. Kiliaan. (2009) S-adenosylmethionine and S-adenosylhomocysteine levels in the aging brain of APP/PS1 Alzheimer mice. Neurological Sciences 30:5, 439-445
CrossRef135
Ciriaco Aguirre Errasti, M. Victoria Egurbide Arberas, Agustín Martínez Berriotxoa. (2009) Homocisteína en la clínica humana. Medicina Clínica 133:12, 472-478
CrossRef136
Jacques Genest, Ruth McPherson, Jiri Frohlich, Todd Anderson, Norm Campbell, André Carpentier, Patrick Couture, Robert Dufour, George Fodor, Gordon A. Francis, Steven Grover, Milan Gupta, Robert A. Hegele, David C. Lau, Lawrence Leiter, Gary F. Lewis, Eva Lonn, G.B. John Mancini, Dominic Ng, Glen J. Pearson, Allan Sniderman, James A. Stone, Ehud Ur. (2009) 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Canadian Journal of Cardiology 25:10, 567-579
CrossRef137
Anna Malinowska, Agata Chmurzynska. (2009) Polymorphism of genes encoding homocysteine metabolism–related enzymes and risk for cardiovascular disease. Nutrition Research 29:10, 685-695
CrossRef138
L L N Husemoen, A Linneberg, M Fenger, B H Thuesen, T Jørgensen. (2009) Changes in lifestyle, biological risk factors and total homocysteine in relation to MTHFR C677T genotype: a 5-year follow-up study. European Journal of Clinical Nutrition 63:10, 1233-1240
CrossRef139
D F Carr, G Whiteley, A Alfirevic, M Pirmohamed. (2009) Investigation of inter-individual variability of the one-carbon folate pathway: a bioinformatic and genetic review. The Pharmacogenomics Journal 9:5, 291-305
CrossRef140
Derrick L. Chandler, Maria T. Llinas, Jane F. Reckelhoff, Babbette LaMarca, Joshua Speed, Joey P. Granger. (2009) Effects of Hyperhomocysteinemia on Arterial Pressure and Nitric Oxide Production in Pregnant Rats. American Journal of Hypertension 22:10, 1115-1119
CrossRef141
Judith Heinz, Siegfried Kropf, Claus Luley, Jutta Dierkes. (2009) Homocysteine as a Risk Factor for Cardiovascular Disease in Patients Treated by Dialysis: A Meta–analysis. American Journal of Kidney Diseases 54:3, 478-489
CrossRef142
Thomas Guttuso, Michael P. McDermott, Phillip Ng, Karl Kieburtz. (2009) Effect of L-methionine on hot flashes in postmenopausal women. Menopause 16:5, 1004-1008
CrossRef143
Niall JJ MacDougall, Sanjay Amarasinghe, Keith W Muir. (2009) Secondary prevention of stroke. Expert Review of Cardiovascular Therapy 7:9, 1103-1115
CrossRef144
Olaf Stanger, Brian Fowler, Klaus Piertzik, Martina Huemer, Elisabeth Haschke-Becher, Alexander Semmler, Stefan Lorenzl, Michael Linnebank. (2009) Homocysteine, folate and vitamin B 12 in neuropsychiatric diseases: review and treatment recommendations. Expert Review of Neurotherapeutics 9:9, 1393-1412
CrossRef145
Xin Zhou, Jun-Xiang Liu, Rui Shi, Ning Yang, Dong-Lin Song, Wei Pang, Yu-Ming Li. (2009) Compound Ion Salt, a Novel Low-Sodium Salt Substitute: From Animal Study to Community-Based Population Trial. American Journal of Hypertension 22:9, 934-942
CrossRef146
Aviv Mager, Katia Orvin, Nira Koren-Morag, Israel Eli Lev, Abid Assali, Ran Kornowski, Mordechai Shohat, Alexander Battler, David Hasdai. (2009) Impact of Homocysteine-Lowering Vitamin Therapy on Long-Term Outcome of Patients With Coronary Artery Disease. The American Journal of Cardiology 104:6, 745-749
CrossRef147
John C. Mathers. (2009) Folate intake and bowel cancer risk. Genes & Nutrition 4:3, 173-178
CrossRef148
G. M. Lindzon, A. Medline, K.-J. Sohn, F. Depeint, R. Croxford, Y.-I. Kim. (2009) Effect of folic acid supplementation on the progression of colorectal aberrant crypt foci. Carcinogenesis 30:9, 1536-1543
CrossRef149
Diego Ingrosso, Alessandra F. Perna. (2009) Epigenetics in hyperhomocysteinemic states. A special focus on uremia. Biochimica et Biophysica Acta (BBA) - General Subjects 1790:9, 892-899
CrossRef150
B. Van Guelpen, J. Hultdin, I. Johansson, C. Witthöft, L. Weinehall, M. Eliasson, G. Hallmans, R. Palmqvist, J.-H. Jansson, A. Winkvist. (2009) Plasma folate and total homocysteine levels are associated with the risk of myocardial infarction, independently of each other and of renal function. Journal of Internal Medicine 266:2, 182-195
CrossRef151
Giuseppe Salemi, M. C. Gueli, M. D’Amelio, V. Saia, P. Mangiapane, P. Aridon, P. Ragonese, I. Lupo. (2009) Blood levels of homocysteine, cysteine, glutathione, folic acid, and vitamin B12 in the acute phase of atherothrombotic stroke. Neurological Sciences 30:4, 361-364
CrossRef152
Arturo J Martí-Carvajal, Andrés Felipe Cardona, Able Lawrence, Arturo J Martí-Carvajal. 2009. Interventions for previously untreated patients with AIDS-associated Non-Hodgkin´s Lymphoma. .
CrossRef153
Amy Kang, Sagar U Nigwekar, Vlado Perkovic, Satyarth Kulshrestha, Sophia Zoungas, Sankar D Navaneethan, Alan Cass, Martin P Gallagher, Toshiharu Ninomiya, Giovanni FM Strippoli, Meg J Jardine, Meg J Jardine. 2009. Interventions for lowering plasma homocysteine levels in kidney transplant recipients. .
CrossRef154
Mary Frances Picciano, Elizabeth A. Yetley, Paul M. Coates, Michelle Kay McGuire. (2009) Update on Folate and Human Health. Nutrition Today 44:4, 142-152
CrossRef155
A.B. Alexandroff, M. Pauriah, R.D.R. Camp, C.C. Lang, A.D. Struthers, D.J. Armstrong. (2009) More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. British Journal of Dermatology 161:1, 1-7
CrossRef156
2009. Risk Assessment for Complications of Diabetes Mellitus. , 195-241.
CrossRef157
Farbod Raiszadeh, Donald R Hoover, Irene Lee, Qiuhu Shi, Kathryn Anastos, Wei Gao, Robert C Kaplan, Marshall J Glesby. (2009) Plasma Homocysteine Is Not Associated With HIV Serostatus or Antiretroviral Therapy in Women. JAIDS Journal of Acquired Immune Deficiency Syndromes 51:2, 175-178
CrossRef158
Concepción Sánchez-Moreno, Antonio Jiménez-Escrig, Antonio Martín. (2009) Stroke: roles of B vitamins, homocysteine and antioxidants. Nutrition Research Reviews 22:01, 49
CrossRef159
Carrie W Nemerovski, Michael P Dorsch, Robert U Simpson, Henry G Bone, Keith D Aaronson, Barry E Bleske. (2009) Vitamin D and Cardiovascular Disease. Pharmacotherapy 29:6, 691-708
CrossRef160
H.-C. Diener, C. Weimar. (2009) Update of secondary stroke prevention. Nephrology Dialysis Transplantation 24:6, 1718-1724
CrossRef161
YG Cao, JG Chai, YC Chen, J Zhao, J Zhou, JP Shao, C Ma, XD Liu, XQ Liu. (2009) Beneficial effects of danshensu, an active component of Salvia miltiorrhiza, on homocysteine metabolism via the trans-sulphuration pathway in rats. British Journal of Pharmacology 157:3, 482-490
CrossRef162
Young-In Kim. (2009) Role of the MTHFR polymorphisms in cancer risk modification and treatment. Future Oncology 5:4, 523-542
CrossRef163
Claudio Napoli, Francesco Cacciatore. (2009) Novel Pathogenic Insights in the Primary Prevention of Cardiovascular Disease. Progress in Cardiovascular Diseases 51:6, 503-523
CrossRef164
Rex L. Jamison, Mei-Chiung Shih, Donald E. Humphries, Peter D. Guarino, James S. Kaufman, David S. Goldfarb, Stuart R. Warren, J. Michael Gaziano, Philip Lavori. (2009) Effect of the MTHFR C677T and A1298C Polymorphisms on Survival in Patients With Advanced CKD and ESRD: A Prospective Study. American Journal of Kidney Diseases 53:5, 779-789
CrossRef165
Peter Nagele, Barbara Zeugswetter, Corinna Eberle, Michael Hüpfl, Martina Mittlböck, Manuela Födinger. (2009) A common gene variant in methionine synthase reductase is not associated with peak homocysteine concentrations after nitrous oxide anesthesia. Pharmacogenetics and Genomics 19:5, 325-329
CrossRef166
Michael A. Thompson, Brent A. Bauer, Laura L. Loehrer, Stephen S. Cha, Jayawant N. Mandrekar, Amit Sood, Dietlind L. Wahner-Roedler. (2009) Dietary Supplement S -Adenosyl-
l -Methionine (AdoMet) Effects on Plasma Homocysteine Levels in Healthy Human Subjects: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. The Journal of Alternative and Complementary Medicine 15:5, 523-529
CrossRef167
Joel B Mason. (2009) Folate, cancer risk, and the Greek god, Proteus: a tale of two chameleons. Nutrition Reviews 67:4, 206-212
CrossRef168
Sandra Hirsch, Hugo Sanchez, Cecilia Albala, María Pía de la Maza, Gladys Barrera, Laura Leiva, Daniel Bunout. (2009) Colon cancer in Chile before and after the start of the flour fortification program with folic acid. European Journal of Gastroenterology & Hepatology 21:4, 436-439
CrossRef169
Tanya GK Bentley, Milton C Weinstein, Walter C Willett, Karen M Kuntz. (2009) A cost-effectiveness analysis of folic acid fortification policy in the United States. Public Health Nutrition 12:04, 455
CrossRef170
(2009) Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. The Lancet 373:9672, 1341-1351
CrossRef171
Scott Mintzer, Christopher T. Skidmore, Caitlin J. Abidin, Megan C. Morales, Inna Chervoneva, David M. Capuzzi, Michael R. Sperling. (2009) Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Annals of Neurology 65:4, 448-456
CrossRef172
Arijit Biswas, Ravi Ranjan, Arvind Meena, Mohammad Suhail Akhter, Birendra Kumar Yadav, Murali Munisamy, Vivekanandhan Subbiah, Madhuri Behari, Renu Saxena. (2009) Homocystine Levels, Polymorphisms and the Risk of Ischemic Stroke in Young Asian Indians. Journal of Stroke and Cerebrovascular Diseases 18:2, 103-110
CrossRef173
Bradley A. Maron, Joseph Loscalzo. (2009) The Treatment of Hyperhomocysteinemia. Annual Review of Medicine 60:1, 39-54
CrossRef174
Ann Van Campenhout, Corey S. Moran, Adam Parr, Paula Clancy, Catherine Rush, Hieronim Jakubowski, Jonathan Golledge. (2009) Role of homocysteine in aortic calcification and osteogenic cell differentiation. Atherosclerosis 202:2, 557-566
CrossRef175
Patricia Casais, Maria F. Alberto, Maria J. Salviú, Susana S. Meschengieser, Monica Aixalá, Maria A. Lazzari. (2009) Pilot study of homocysteine and cysteine in patients with thrombosis in different vascular sites. Epidemiology and response to folate. Thrombosis Research 123:4, 592-596
CrossRef176
Andrew G. Bostom, Myra A. Carpenter, Lawrence Hunsicker, Paul F. Jacques, John W. Kusek, Andrew S. Levey, Joyce L. McKenney, Renee Y. Mercier, Marc A. Pfeffer, Jacob Selhub. (2009) Baseline Characteristics of Participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. American Journal of Kidney Diseases 53:1, 121-128
CrossRef177
R A M Dhonukshe-Rutten, J H M de Vries, A de Bree, N van der Put, W A van Staveren, L C P G M de Groot. (2009) Dietary intake and status of folate and vitamin B12 and their association with homocysteine and cardiovascular disease in European populations. European Journal of Clinical Nutrition 63:1, 18-30
CrossRef178
Cheryl D. Bushnell, Cathleen S. Colón-Emeric. (2009) Secondary Stroke Prevention Strategies for the Oldest Patients. Drugs & Aging 26:3, 209-230
CrossRef179
M. Dunkelgrun, S. E. Hoeks, O. Schouten, H. H. H. Feringa, G. M. J. M. Welten, R. Vidakovic, Y. R. B. M. van Gestel, R. T. van Domburg, D. Goei, R. de Jonge, J. Lindemans, D. Poldermans. (2009) Methionine loading does not enhance the predictive value of homocysteine serum testing for all-cause mortality or major adverse cardiac events. Internal Medicine Journal 39:1, 13-18
CrossRef180
Adriano Sabino, Ana Paula Fernandes, Luciana Moreira Lima, Daniel Dias Ribeiro, Marinez Oliveira Sousa, Maria Elizabeth Rennó Castro Santos, Ana Paula Lucas Mota, Luci Maria Sant’Ana Dusse, Maria Graças Carvalho. (2009) Polymorphism in the methylenetetrahydrofolate reductase (C677T) gene and homocysteine levels: a comparison in Brazilian patients with coronary arterial disease, ischemic stroke and peripheral arterial obstructive disease. Journal of Thrombosis and Thrombolysis 27:1, 82-87
CrossRef181
Wei-guo Zhu, Shan Li, Le-qing Lin, Hui Yan, Ting Fu, Jian-hua Zhu. (2009) Vascular oxidative stress increases dendritic cell adhesion and transmigration induced by homocysteine. Cellular Immunology 254:2, 110-116
CrossRef182
Julia Sauer, Joel B Mason, Sang-Woon Choi. (2009) Too much folate: a risk factor for cancer and cardiovascular disease?. Current Opinion in Clinical Nutrition and Metabolic Care 12:1, 30-36
CrossRef183
Denis Xavier, Prem Pais, Alben Sigamani, Janice Pogue, Rizwan Afzal, Salim Yusuf. (2008) The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study. Nature Clinical Practice Cardiovascular Medicine 6:2, 96-97
CrossRef184
Mohamad Sidani, Carol Ziegler. (2008) Preventing Heart Disease: Who Needs to be Concerned and What to Do. Primary Care: Clinics in Office Practice 35:4, 589-607
CrossRef185
Jessica Kendrick, Michel B Chonchol. (2008) Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nature Clinical Practice Nephrology 4:12, 672-681
CrossRef186
Teruhiko Koike, Masafumi Kuzuya, Shigeru Kanda, Kiwako Okada, Sachiko Izawa, Hiromi Enoki, Akihisa Iguchi. (2008) Raised homocysteine and low folate and vitamin B-12 concentrations predict cognitive decline in community-dwelling older Japanese adults. Clinical Nutrition 27:6, 865-871
CrossRef187
Jiangtao Yan, Zhengliang Yue, Jiaomei Shao, Rutai Hui, Daowen Wang. (2008) Predication of increased plasma homocysteine level on the prognosis of Chinese patients with first-onset ischemic stroke. Frontiers of Medicine in China 2:4, 352-355
CrossRef188
Venket Rao, Amir Al-Weshahy. (2008) Plant-based diets and control of lipids and coronary heart disease risk. Current Atherosclerosis Reports 10:6, 478-485
CrossRef189
Timothy Kwok, Jones Chun-Man Chan. (2008) Vitamin B 12 and health in old age. Aging Health 4:6, 651-657
CrossRef190
Mary A. T. Flynn, Wayne A. Anderson, Sarah J. Burke, Alan Reilly. (2008) Session 1: Public health nutrition Folic acid food fortification: the Irish experience. Proceedings of the Nutrition Society 67:04, 381
CrossRef191
Philip A Wood. (2008) Potential of nutrigenetics in the treatment of metabolic disorders. Expert Review of Endocrinology & Metabolism 3:6, 705-713
CrossRef192
Karin Nilsson, Lars Gustafson, Björn Hultberg. (2008) Plasma homocysteine and vascular disease in elderly patients with mental illness. Clinical Chemistry and Laboratory Medicine 46:11, 1556-1561
CrossRef193
L. L. Humphrey, R. Fu, K. Rogers, M. Freeman, M. Helfand. (2008) Homocysteine Level and Coronary Heart Disease Incidence: A Systematic Review and Meta-analysis. Mayo Clinic Proceedings 83:11, 1203-1212
CrossRef194
J. Sobesky. (2008) Schlaganfallprävention jenseits der Apotheke. Der Nervenarzt 79:10, 1156-1163
CrossRef195
J.B. Richards, A.M. Valdes, J.P. Gardner, B.S. Kato, A. Siva, M. Kimura, X. Lu, M.J. Brown, A. Aviv, T.D. Spector. (2008) Homocysteine levels and leukocyte telomere length. Atherosclerosis 200:2, 271-277
CrossRef196
John S. Lane, Cheryl P. Magno, Karen T. Lane, Tyler Chan, David B. Hoyt, Sheldon Greenfield. (2008) Nutrition impacts the prevalence of peripheral arterial disease in the United States. Journal of Vascular Surgery 48:4, 897-904.e1
CrossRef197
M. Ranucci, A. Ballotta, A. Frigiola, A. Boncilli, S. Brozzi, E. Costa, R. H. Mehta. (2008) Pre-operative homocysteine levels and morbidity and mortality following cardiac surgery. European Heart Journal 30:8, 995-1004
CrossRef198
Joanna Perła-Kaján, Olaf Stanger, Michał Łuczak, Agnieszka Ziółkowska, Ludwik K. Malendowicz, Tomasz Twardowski, Šárka Lhotak, Richard C. Austin, Hieronim Jakubowski. (2008) Immunohistochemical detection of N-homocysteinylated proteins in humans and mice. Biomedicine & Pharmacotherapy 62:7, 473-479
CrossRef199
Francisco Martin-Herrero, Javier Jiménez-Candil, Javier Martín-Moreiras, Pedro Pabón, Ignacio Cruz-González, Ana Martín-García, Victor León, Cándido Martín-Luengo. (2008) Homocysteine, Cause or Consequence?. International Journal of Cardiology 129:2, 276-277
CrossRef200
Alessandro Valli, Juan J. Carrero, Abdul Rashid Qureshi, Giacomo Garibotto, Peter Bárány, Jonas Axelsson, Bengt Lindholm, Peter Stenvinkel, Björn Anderstam, Mohamed E. Suliman. (2008) Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients. Clinica Chimica Acta 395:1-2, 106-110
CrossRef201
Michael D. Sosin, Jeetesh V. Patel, Gurbir S. Bhatia, Elizabeth A. Hughes, Russell C. Davis, Gregory Y.H. Lip. (2008) Effects of White European, African Caribbean and South Asian ethnicity on homocysteine levels in patients with systolic heart failure. International Journal of Cardiology 129:1, 69-75
CrossRef202
Emile Mohler, Jay Giri. (2008) Management of peripheral arterial disease patients: comparing the ACC/AHA and TASC-II guidelines. Current Medical Research and Opinion 24:9, 2509-2522
CrossRef203
Niels Engberding, Nanette K Wenger. (2008) Cardiovascular disease prevention tailored for women. Expert Review of Cardiovascular Therapy 6:8, 1123-1134
CrossRef204
Barry A Franklin, Justin E Trivax, Thomas E Vanhecke. (2008) New insights in preventive cardiology and cardiac rehabilitation. Current Opinion in Cardiology 23:5, 477-486
CrossRef205
Konstantinos Tziomalos, Charitha N. Weerasinghe, Dimitri P. Mikhailidis, Alexander M. Seifalian. (2008) Vascular risk factors in South Asians. International Journal of Cardiology 128:1, 5-16
CrossRef206
Anke-Hilse Maitland-van der Zee, Amy Lynch, Eric Boerwinkle, Donna K. Arnett, Barry R. Davis, Catherine Leiendecker-Foster, Charles E. Ford, John H. Eckfeldt. (2008) Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study. Pharmacogenetics and Genomics 18:8, 651-656
CrossRef207
C. Antoniades, A. S. Antonopoulos, D. Tousoulis, K. Marinou, C. Stefanadis. (2008) Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. European Heart Journal 30:1, 6-15
CrossRef208
Martijn G.H. van Oijen, Bimmer E.P.M. Claessen, Nick Clappers, Annie van Schaik, Robert J.F. Laheij, Jan B.M.J. Jansen, Wilbert H.M. Peters, Freek W.A. Verheugt. (2008) Prognostic Value of Free Plasma Homocysteine Levels in Patients Hospitalized With Acute Coronary Syndrome. The American Journal of Cardiology 102:2, 135-139
CrossRef209
Priyanka Sharma, Jitender Kumar, Gaurav Garg, Arun Kumar, Ashok Patowary, Ganesan Karthikeyan, Lakshmy Ramakrishnan, Vani Brahmachari, Shantanu Sengupta. (2008) Detection of Altered Global DNA Methylation in Coronary Artery Disease Patients. DNA and Cell Biology 27:7, 357-365
CrossRef210
Amytis Towfighi, Jeffrey L. Saver, Rita Engelhardt, Bruce Ovbiagele. (2008) Factors Associated with the Steep Increase in Late Midlife Stroke Occurrence among US Men. Journal of Stroke and Cerebrovascular Diseases 17:4, 165-168
CrossRef211
Thomas Guttuso, Michael P. McDermott, Haiyan Su, Karl Kieburtz. (2008) Effects of L-Isoleucine and L-Valine on Hot Flushes and Serum Homocysteine. Obstetrics & Gynecology 112:1, 109-115
CrossRef212
H. Stopper, A.-T. Treutlein, U. Bahner, N. Schupp, U. Schmid, A. Brink, A. Perna, A. Heidland. (2008) Reduction of the genomic damage level in haemodialysis patients by folic acid and vitamin B12 supplementation. Nephrology Dialysis Transplantation 23:10, 3272-3279
CrossRef213
Yi-Fei Zhang, Guang Ning. (2008) Mecobalamin. Expert Opinion on Investigational Drugs 17:6, 953-964
CrossRef214
Tonje Holte Stea, Mohammad Azam Mansoor, Margareta Wandel, Solveig Uglem, Wenche Frølich. (2008) Changes in predictors and status of homocysteine in young male adults after a dietary intervention with vegetables, fruits and bread. European Journal of Nutrition 47:4, 201-209
CrossRef215
B. I. HIRSCHOWITZ, J. WORTHINGTON, J. MOHNEN. (2008) Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Alimentary Pharmacology & Therapeutics 27:11, 1110-1121
CrossRef216
Omar Obeid, Lynn Al Khatib, Malek Batal, Nada Adra, Nahla Hwalla. (2008) Established and Suspected Biomarkers of Cardiovascular Disease (CVD) Risk in Pre-Menopausal Lebanese Women. Ecology of Food and Nutrition 47:3, 298-311
CrossRef217
Inger Anne Næss, Sverre C. Christiansen, Pål R. Romundstad, Suzanne C. Cannegieter, Henk J. Blom, Frits R. Rosendaal, Jens Hammerstrøm. (2008) Prospective study of homocysteine and MTHFR 677TT genotype and risk for venous thrombosis in a general population – results from the HUNT 2 study. British Journal of Haematology 141:4, 529-535
CrossRef218
Niels P. Riksen, Gerard A. Rongen, Derek Yellon, Paul Smits. (2008) Human in vivo research on the vascular effects of adenosine. European Journal of Pharmacology 585:2-3, 220-227
CrossRef219
Lin Chang, Bin Geng, Fang Yu, Jing Zhao, Hongfeng Jiang, Junbao Du, Chaoshu Tang. (2008) Hydrogen sulfide inhibits myocardial injury induced by homocysteine in rats. Amino Acids 34:4, 573-585
CrossRef220
Anna M. Dahlin, Bethany Van Guelpen, Johan Hultdin, Ingegerd Johansson, Göran Hallmans, Richard Palmqvist. (2008) Plasma vitamin B12 concentrations and the risk of colorectal cancer: A nested case-referent study. International Journal of Cancer 122:9, 2057-2061
CrossRef221
Franca Moschiano, Domenico D’Amico, Susanna Usai, Licia Grazzi, Maria Stefano, Emilio Ciusani, Nicoletta Erba, Gennaro Bussone. (2008) Homocysteine plasma levels in patients with migraine with aura. Neurological Sciences 29:S1, 173-175
CrossRef222
Helene McNulty, Kristina Pentieva, Leane Hoey, Mary Ward. (2008) Homocysteine, B-vitamins and CVD. Proceedings of the Nutrition Society 67:02, 232-237
CrossRef223
Jose B. Nevado, Marcelo Severino B. Imasa. (2008) Homocysteine predicts adverse clinical outcomes in unstable angina and non-ST elevation myocardial infarction: implications from the folate intervention in non-ST elevation myocardial infarction and unstable angina study. Coronary Artery Disease 19:3, 153-161
CrossRef224
J. David Spence. (2008) Polypill: for Pollyanna. International Journal of Stroke 3:2, 92-97
CrossRef225
Katharina Schroecksnadel, Roland B. Walter, Guenter Weiss, Michael Mark, Walter H. Reinhart, Dietmar Fuchs. (2008) Association between plasma thiols and immune activation marker neopterin in stable coronary heart disease. Clinical Chemistry and Laboratory Medicine 46:5, 648-654
CrossRef226
M. Shimano, Y. Inden, Y. Tsuji, H. Kamiya, T. Uchikawa, R. Shibata, T. Murohara. (2008) Circulating homocysteine levels in patients with radiofrequency catheter ablation for atrial fibrillation. Europace 10:8, 961-966
CrossRef227
Randee Silverman, Jeremy Brauer. 2008. Vitamins. , 221-247.
CrossRef228
Gere Sunder-Plassmann, Wolfgang C. Winkelmayer, Manuela Födinger. (2008) Approaching the End of the Homocysteine Hype?. American Journal of Kidney Diseases 51:4, 549-553
CrossRef229
J. Willeit, S. Kiechl, F. Aichner, K. Berek, H. Binder, M. Brainin, F. Fazekas, G. Fraedrich, H.P. Haring, S. Horner, B. Iglseder, P. Kapeller, W. Lang, E. Minar, K. Niederkorn, G. Noisternig, M. Schillinger, R. Schmidt, E. Schmutzhard, P. Waldenberger, H.W. Wege. (2008) Positionspapier der Österreichischen Gesellschaft für Schlaganfallforschung. Gefässchirurgie 13:2, 115-125
CrossRef230
Jayanta Das, Sanjay Kaul. (2008) Is homocysteine a relevant cardiovascular risk factor?. Current Cardiovascular Risk Reports 2:2, 141-149
CrossRef231
Michael Rychlik, Sieghard T. Adam. (2008) Glucosinolate and folate content in sprouted broccoli seeds. European Food Research and Technology 226:5, 1057-1064
CrossRef232
Nanette K. Wenger. (2008) Preventing Cardiovascular Disease in Women: An Update. Clinical Cardiology 31:3, 109-113
CrossRef233
G W Dalmeijer, M R Olthof, P Verhoef, M L Bots, Y T van der Schouw. (2008) Prospective study on dietary intakes of folate, betaine, and choline and cardiovascular disease risk in women. European Journal of Clinical Nutrition 62:3, 386-394
CrossRef234
Nicolas W. Shammas, Eric J. Dippel, Michael Jerin, Peter P. Toth, Matthew Kapalis, Mythri Reddy, Harb Harb. (2008) Elevated Levels of Homocysteine Predict Cardiovascular Death, Nonfatal Myocardial Infarction, and Symptomatic Bypass Graft Disease at 2-Year Follow-Up Following Coronary Artery Bypass Surgery. Preventive Cardiology 11:2, 95-99
CrossRef235
Kathleen Woolf, Melinda M. Manore. (2008) Elevated Plasma Homocysteine and Low Vitamin B-6 Status in Nonsupplementing Older Women with Rheumatoid Arthritis. Journal of the American Dietetic Association 108:3, 443-453
CrossRef236
Yung-Wei Chi, Michael R. Jaff. (2008) Optimal risk factor modification and medical management of the patient with peripheral arterial disease. Catheterization and Cardiovascular Interventions 71:4, 475-489
CrossRef237
Pantel S. Vokonas, William B. Kannel. 2008. Epidemiology of Coronary Heart Disease in the Elderly. , 215-242.
CrossRef238
C. P. Lin, Y. H. Chen, W. T. Lin, H. B. Leu, T. Z. Liu, S. L. Huang, J. W. Chen. (2008) Direct effect of statins on homocysteine-induced endothelial adhesiveness: potential impact to human atherosclerosis. European Journal of Clinical Investigation 38:2, 106-116
CrossRef239
J. Willeit, S. Kiechl, F. Aichner, K. Berek, H. Binder, M. Brainin, F. Fazekas, G. Fraedrich, H.P. Haring, S. Horner, B. Iglseder, P. Kapeller, W. Lang, E. Minar, K. Niederkorn, G. Noisternig, M. Schillinger, R. Schmidt, E. Schmutzhard, P. Waldenberger, H.W. Wege. (2008) Positionspapier der Österreichischen Gesellschaft für Schlaganfallforschung. Gefässchirurgie 13:1, 31-41
CrossRef240
Geert A. Martens, Joeri De Nayer, Dieter De Smet, Pedro Couck, Frans Gorus, Erik Gerlo. (2008) Homocysteine measurement by Vitros ® Microtip homocysteine assay. Clinical Chemistry and Laboratory Medicine 46:2, 283-286
CrossRef241
Linda Van Horn, Mikelle McCoin, Penny M. Kris-Etherton, Frances Burke, Jo Ann S. Carson, Catherine M. Champagne, Wahida Karmally, Geeta Sikand. (2008) The Evidence for Dietary Prevention and Treatment of Cardiovascular Disease. Journal of the American Dietetic Association 108:2, 287-331
CrossRef242
Mark Y. Chan, Richard C. Becker. (2008) Identification and treatment of arterial thrombophilia. Current Treatment Options in Cardiovascular Medicine 10:1, 3-11
CrossRef243
Koichi Miyaki, Yoshimitsu Takahashi, Yixuan Song, Ling Zhang, Masaaki Muramatsu, Takeo Nakayama. (2008) Increasing the Number of SNP loci does not Necessarily Improve Prediction Power at Least in the Comparison of MTHFR SNP and Haplotypes. Journal of Epidemiology 18:6, 243-250
CrossRef244
N K Wenger, L J Shaw, V Vaccarino. (2008) Coronary Heart Disease in Women: Update 2008. Clinical Pharmacology & Therapeutics 83:1, 37-51
CrossRef245
Richard F.A. Logan, Matthew J. Grainge, Vic C. Shepherd, Nicholas C. Armitage, Kenneth R. Muir. (2008) Aspirin and Folic Acid for the Prevention of Recurrent Colorectal Adenomas. Gastroenterology 134:1, 29-38
CrossRef246
Tamio Teramoto, Jun Sasaki, Hirotsugu Ueshima, Genshi Egusa, Makoto Kinoshita, Kazuaki Shimamoto, Hiroyuki Daida, Sadatoshi Biro, Kazuhiko Hirobe, Tohru Funahashi, Koutaro Yokote, Masayuki Yokode. (2008) Treatment - Therapeutic Lifestyle Modification. Journal of Atherosclerosis and Thrombosis 15:3, 109-115
CrossRef247
Alessandra F. Perna, Maria Grazia Luciano, Paola Pulzella, Ersilia Satta, Rosanna Capasso, Cinzia Lombardi, Diego Ingrosso, Natale G. De Santo. (2008) Is Homocysteine Toxic in Uremia?. Journal of Renal Nutrition 18:1, 12-17
CrossRef248
RICHARD B. JOHNSTON. (2008) Will Increasing Folic Acid in Fortified Grain Products Further Reduce Neural Tube Defects without Causing Harm?: Consideration of the Evidence. Pediatric Research 63:1, 2-8
CrossRef249
Marci Goldstein Adams, Stacie Geller, Laura Studee. 2007. Menopause and Midlife. .
CrossRef250
K. Fink, A. Brink, J. Vienken, A. Heidland, H. Stopper. (2007) Homocysteine exerts genotoxic and antioxidative effects in vitro. Toxicology in Vitro 21:8, 1402-1408
CrossRef251
Wolfgang Herrmann. (2007) Homocysteine research: alive and kicking!. Clinical Chemistry and Laboratory Medicine 45:12, 1571-1574
CrossRef252
J. David Spence. (2007) Perspective on the efficacy analysis of the Vitamin Intervention for Stroke Prevention trial. Clinical Chemistry and Laboratory Medicine 45:12, 1582-1585
CrossRef253
Gian Paolo Rossi, Teresa Maria Seccia, Achille Cesare Pessina. (2007) Homocysteine, left ventricular dysfunction and coronary artery disease: is there a link?. Clinical Chemistry and Laboratory Medicine 45:12, 1645-1651
CrossRef254
Dan Liao, Xiaofeng Yang, Hong Wang. (2007) Hyperhomocysteinemia and high-density lipoprotein metabolism in cardiovascular disease. Clinical Chemistry and Laboratory Medicine 45:12, 1652-1659
CrossRef255
Eva Lonn. (2007) Homocysteine in the prevention of ischemic heart disease, stroke and venous thromboembolism: therapeutic target or just another distraction?. Current Opinion in Internal Medicine 6:6, 600-606
CrossRef256
Rima Obeid, Andrew McCaddon, Wolfgang Herrmann. (2007) The role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric diseases. Clinical Chemistry and Laboratory Medicine 45:12, 1590-1606
CrossRef257
Wolfgang Herrmann, Markus Herrmann, Jacob Joseph, Suresh C. Tyagi. (2007) Homocysteine, brain natriuretic peptide and chronic heart failure: a critical review. Clinical Chemistry and Laboratory Medicine 45:12, 1633-1644
CrossRef258
Caroline Moats, Eric B. Rimm. (2007) Vitamin intake and risk of coronary disease: Observation versus intervention. Current Atherosclerosis Reports 9:6, 508-514
CrossRef259
J E Baggott, T Tamura. (2007) Iron-dependent formation of homocysteine from methionine and other thioethers. European Journal of Clinical Nutrition 61:12, 1359-1363
CrossRef260
Md S. Jamaluddin, Xiaofeng Yang, Hong Wang. (2007) Hyperhomocysteinemia, DNA methylation and vascular disease. Clinical Chemistry and Laboratory Medicine 45:12, 1660-1666
CrossRef261
Alessandra F. Perna, Filomena Acanfora, Maria Grazia Luciano, Paola Pulzella, Rosanna Capasso, Ersilia Satta, Lombardi Cinzia, Rosa Maria Pollastro, Simona Iannelli, Diego Ingrosso, Natale G. De Santo. (2007) Plasma protein homocysteinylation in uremia. Clinical Chemistry and Laboratory Medicine 45:12, 1678-1682
CrossRef262
Marco Righetti. (2007) Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Clinical Chemistry and Laboratory Medicine 45:12, 1586-1589
CrossRef263
Rowena G. Matthews, C. Lee Elmore. (2007) Defects in homocysteine metabolism: diversity among hyperhomocyst(e)inemias. Clinical Chemistry and Laboratory Medicine 45:12, 1700-1703
CrossRef264
Markus Herrmann, Johannes Peter Schmidt, Natalia Umanskaya, Alexandra Wagner, Omid Taban-Shomal, Thomas Widmann, Graziana Colaianni, Britt Wildemann, Wolfgang Herrmann. (2007) The role of hyperhomocysteinemia as well as folate, vitamin B 6 and B 12 deficiencies in osteoporosis – a systematic review. Clinical Chemistry and Laboratory Medicine 45:12, 1621-1632
CrossRef265
(2007) Homocysteine-lowering trials for prevention of vascular disease: protocol for a collaborative meta-analysis. Clinical Chemistry and Laboratory Medicine 45:12, 1575-1581
CrossRef266
Hieronim Jakubowski. (2007) The molecular basis of homocysteine thiolactone-mediated vascular disease. Clinical Chemistry and Laboratory Medicine 45:12, 1704-1716
CrossRef267
H R Nakhai-Pour, D E Grobbee, M L Bots, M Muller, Y T van der Schouw. (2007) Circulating homocysteine and large arterial stiffness and thickness in a population-based sample of middle-aged and elderly men. Journal of Human Hypertension 21:12, 942-948
CrossRef268
Wang, Rui, Lagakos, Stephen W., Ware, James H., Hunter, David J., Drazen, Jeffrey M., . (2007) Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials. New England Journal of Medicine 357:21, 2189-2194
Full Text269
C. Lee Elmore, Rowena G. Matthews. (2007) The Many Flavors of Hyperhomocyst(e)inemia: Insights from Transgenic and Inhibitor-Based Mouse Models of Disrupted One-Carbon Metabolism. Antioxidants & Redox Signaling 9:11, 1911-1922
CrossRef270
Young-In Kim. (2007) Folic Acid Fortification and Supplementation-Good for Some but Not So Good for Others. Nutrition Reviews 65:11, 504-511
CrossRef271
Paul Haggarty. (2007) B-vitamins, genotype and disease causality. Proceedings of the Nutrition Society 66:04,
CrossRef272
Mohamed E. Suliman, Bengt Lindholm, Peter Bárány, Abdul Rashid Qureshi, Peter Stenvinkel. (2007) CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Homocysteine-Lowering Is Not a Primary Target for Cardiovascular Disease Prevention in Chronic Kidney Disease Patients. Seminars in Dialysis 20:6, 523-529
CrossRef273
Louisa Papatheodorou, Norbert Weiss. (2007) Vascular Oxidant Stress and Inflammation in Hyperhomocysteinemia. Antioxidants & Redox Signaling 9:11, 1941-1958
CrossRef274
Michael Lever, Wendy Atkinson, Peter M. George, Stephen T. Chambers. (2007) Sex differences in the control of plasma concentrations and urinary excretion of glycine betaine in patients attending a lipid disorders clinic. Clinical Biochemistry 40:16-17, 1225-1231
CrossRef275
Edith Lubos, Joseph Loscalzo, Diane E. Handy. (2007) Homocysteine and Glutathione Peroxidase-1. Antioxidants & Redox Signaling 9:11, 1923-1940
CrossRef276
Nanette K. Wenger. (2007) Do Diet, Folic Acid, and Vitamins Matter?. Cardiology in Review 15:6, 288-290
CrossRef277
Jerrilynn D. Burrowes. (2007) Preventing Heart Disease in Women. Nutrition Today 42:6, 242-247
CrossRef278
Bradley A. Maron, Joseph Loscalzo. (2007) Should hyperhomocysteinemia be treated in patients with atherosclerotic disease?. Current Atherosclerosis Reports 9:5, 375-383
CrossRef279
Rachel Dankner, Angela Chetrit, Gie Ken Dror, Ben-Ami Sela. (2007) Physical activity is inversely associated with total homocysteine levels, independent of C677T MTHFR genotype and plasma B vitamins. AGE 29:4, 219-227
CrossRef280
Robert S. Rosenson, Christine C. Tangney. (2007) Preanalytical sources of measurement error: The conundrum of the homocysteine hypothesis. Atherosclerosis 194:2, 520
CrossRef281
M. J. Alberts, B. Ovbiagele. (2007) Current strategies for ischemic stroke prevention: role of multimodal combination therapies. Journal of Neurology 254:10, 1414-1426
CrossRef282
Patricia F. Coogan, Lynn Rosenberg. (2007) The use of folic acid antagonists and the risk of colorectal cancer. Pharmacoepidemiology and Drug Safety 16:10, 1111-1119
CrossRef283
R. Weber, H.C. Diener, M. Grond. (2007) Aktuelle Aspekte der Sekundärprophylaxe des ischämischen Schlaganfalls. Der Nervenarzt 78:10, 1138-1146
CrossRef284
M H T Ridinger. (2007) Nutraceuticals: Miracle or Meme?. Clinical Pharmacology & Therapeutics 82:4, 352-356
CrossRef285
Tomohiro Okura, Yoshio Nakata, Kazunori Ohkawara, Shigeharu Numao, Yasutomi Katayama, Yohei Ono, Tomoaki Matsuo, Hirohito Sone, Kiyoji Tanaka. (2007) Effect of weight reduction on concentration of plasma total homocysteine in obese Japanese men. Obesity Research & Clinical Practice 1:3, 213-221
CrossRef286
S. Sacco, A. Carolei. (2007) Homocysteine and leukoaraiosis: time for a clinical trial?. Neurological Sciences 28:5, 235-237
CrossRef287
Mary J. Roman, Mary K. Crow, Michael D. Lockshin, Richard B. Devereux, Stephen A. Paget, Lisa Sammaritano, Daniel M. Levine, Adrienne Davis, Jane E. Salmon. (2007) Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis & Rheumatism 56:10, 3412-3419
CrossRef288
&NA;. (2007) FULL TEXT Chapter 1: Introduction. European Journal of Cardiovascular Prevention & Rehabilitation 14:Supplement 2, S2-S113
CrossRef289
M. Weih, J. Wiltfang, J. Kornhuber. (2007) Non-pharmacologic prevention of Alzheimer’s disease: nutritional and life-style risk factors. Journal of Neural Transmission 114:9, 1187-1197
CrossRef290
D Serón, F Moreso. (2007) Protocol biopsies in renal transplantation: Prognostic value of structural monitoring. Kidney International 72:6, 690-697
CrossRef291
J David Spence. (2007) Homocysteine-lowering therapy: a role in stroke prevention?. The Lancet Neurology 6:9, 830-838
CrossRef292
José M. García-Pinilla, Salvador Espinosa-Caliani, Juan J. Gómez-Doblas, Manuel F. Jiménez-Navarro, Fernando Cabrera-Bueno, Encarnación Muñoz Morán, Maximiliano Ruiz-Galdón, Armando Reyes-Engel, Eduardo de Teresa Galván. (2007) Hiperhomocisteinemia moderada, déficit basal de folatos y pronóstico del síndrome coronario agudo sin elevación del segmento ST. Medicina Clínica 129:8, 281-286
CrossRef293
Ronald Krauss, Patty Siri-Tarino, Elaine Feldman. 2007. Effects of Diet on Cardiovascular Disease Risk. , 727-734.
CrossRef294
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliot M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction—Executive Summary. Journal of the American College of Cardiology 50:7, 652-726
CrossRef295
Ø. Bleie, A. G. Semb, H. Grundt, J. E. Nordrehaug, S. E. Vollset, P. M. Ueland, D. W. T. Nilsen, A. M. Bakken, H. Refsum, O. K. Nygård. (2007) Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease. Journal of Internal Medicine 262:2, 244-253
CrossRef296
J David Spence. (2007) Stroke prevention in the high-risk patient. Expert Opinion on Pharmacotherapy 8:12, 1851-1859
CrossRef297
Tzu
Yuan Chang, Kang-Ju Chou, Chin
CrossRef298
Mei Ni, Xing Hua Zhang, Shi Liang Jiang, Yun Zhang. (2007) Homocystinemia as an Independent Risk Factor in the Chinese Population at a High Risk of Coronary Artery Disease. The American Journal of Cardiology 100:3, 455-458
CrossRef299
Sandra G. Heil, Leo A. Kluijtmans, An S. De Vriese, Rolph Pfundt, Henk J. Blom. (2007) Diet-induced hyperhomocysteinemia does not lead to large gene-expression differences in rat aorta. Atherosclerosis 193:2, 452-454
CrossRef300
Charles J. Glueck, Jitender Munjal, Dawit Aregawi, Maliha Agloria, Magdalena Winiarska, Qasim Khalil, Ping Wang. (2007) Thrombophilia–hypofibrinolysis and atherothrombotic cardiovascular disease ≤ age 45 years. Translational Research 150:2, 93-100
CrossRef301
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliott M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 50:7, e1-e157
CrossRef302
G. Le Gal, A. Delluc. (2007) Faut-il encore se préoccuper de l'homocystéinémie des patients atteints de maladie veineuse thromboembolique?. La Revue de Médecine Interne 28:8, 517-519
CrossRef303
Arturo J Martí-Carvajal, Georgia Salanti, Ricardo Hidalgo, Agustín Ciapponi, Arturo J Martí-Carvajal. 2007. Homocysteine lowering interventions for preventing cardiovascular events. .
CrossRef304
Peter Muennig, Nancy Sohler, Bisundev Mahato. (2007) Socioeconomic status as an independent predictor of physiological biomarkers of cardiovascular disease: Evidence from NHANES. Preventive Medicine 45:1, 35-40
CrossRef305
Jeremy Marcus, Mark J. Sarnak, Vandana Menon, Subodh Verma. (2007) Homocysteine lowering and cardiovascular disease risk: Lost in translation. Canadian Journal of Cardiology 23:9, 707-710
CrossRef306
Laura E. Middleton, Susan A. Kirkland, Colleen J. Maxwell, David B. Hogan, Kenneth Rockwood. (2007) Exercise: A Potential Contributing Factor to the Relationship Between Folate and Dementia. Journal of the American Geriatrics Society 55:7, 1095-1098
CrossRef307
Jessica A. Sipkens, Paul A. J. Krijnen, Christof Meischl, Saskia A. G. M. Cillessen, Yvo M. Smulders, Desirée E. C. Smith, Cindy P. E. Giroth, Marieke D. Spreeuwenberg, René J. P. Musters, Alice Muller, Cornelis Jakobs, Dirk Roos, Coen D. A. Stehouwer, Jan A. Rauwerda, Victor W. M. Hinsbergh, Hans W. M. Niessen. (2007) Homocysteine affects cardiomyocyte viability: concentration-dependent effects on reversible flip-flop, apoptosis and necrosis. Apoptosis 12:8, 1407-1418
CrossRef308
Xiaobin Wang, Xianhui Qin, Hakan Demirtas, Jianping Li, Guangyun Mao, Yong Huo, Ningling Sun, Lisheng Liu, Xiping Xu. (2007) Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. The Lancet 369:9576, 1876-1882
CrossRef309
Cesare R Sirtori, James W Anderson, Anna Arnoldi. (2007) Nutritional and nutraceutical considerations for dyslipidemia. Future Lipidology 2:3, 313-339
CrossRef310
Jean-Claude Tardif, Michel Carrier, David E. Kandzari, Robert Emery, Robert Cote, Therese Heinonen, Marjorie Zettler, Vic Hasselblad, Marie-Claude Guertin, Robert A. Harrington. (2007) Effects of pyridoxal-5′-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: Results of the MEND-CABG randomized study. The Journal of Thoracic and Cardiovascular Surgery 133:6, 1604-1611.e1
CrossRef311
Cynthia M Carlsson. (2007) Lowering homocysteine for stroke prevention. The Lancet 369:9576, 1841-1842
CrossRef312
Diane Nykamp, Edie D. Kavanaugh, Amy P. Wenker. (2007) <b>Vitamins: The Wise Choice for Women with Cardiovascular Disease</b>. The Consultant Pharmacist 22:6, 490-502
CrossRef313
Jacqueline Suk Danik, Paul M. Ridker. (2007) Genetic determinants of C-reactive protein. Current Atherosclerosis Reports 9:3, 195-203
CrossRef314
José Manuel García-Pinilla, Salvador Espinosa-Caliani, Juan José Gómez-Doblas, Manuel Jiménez-Navarro, María J. Gaitán, Encarnación Muñoz-Morán, Fernando Cabrera-Bueno, José M. Hernández-García, María Victoria Ortega-Jiménez, Maximiliano Ruiz-Galdón, Armando Reyes-Engel, Eduardo de Teresa-Galván. (2007) Influence of high homocysteine and low folate plasmatic levels in medium-term prognosis after acute coronary syndromes. International Journal of Cardiology 118:2, 220-226
CrossRef315
B. Iglseder. (2007) Jeder einzelne Risikofaktor zählt!. focus neurogeriatrie 1:1, 14-15
CrossRef316
Karol E. Watson. (2007) Homocysteine lowering and cardiovascular events after acute myocardial infarction. Current Cardiovascular Risk Reports 1:2, 95-96
CrossRef317
J. MANRIQUE, P. ERRASTI, J. ORBE, J. A. PÁRAMO, J. A. RODRÍGUEZ. (2007) Folic acid and B vitamins improve hyperhomocysteinemia-induced cardiovascular risk profile in renal transplant recipients. Journal of Thrombosis and Haemostasis 5:5, 1072-1076
CrossRef318
Steinar Hustad, Øivind Midttun, Jørn Schneede, Stein Emil Vollset, Tom Grotmol, Per Magne Ueland. (2007) The Methylenetetrahydrofolate Reductase 677C→T Polymorphism as a Modulator of a B Vitamin Network with Major Effects on Homocysteine Metabolism. The American Journal of Human Genetics 80:5, 846-855
CrossRef319
Anita C. Peeters, Bart A. van Landeghem, Sietze J. Graafsma, Steef E. Kranendonk, Ad R. Hermus, Henk J. Blom, Martin den Heijer. (2007) Low vitamin B6, and not plasma homocysteine concentration, as risk factor for abdominal aortic aneurysm: A retrospective case–control study. Journal of Vascular Surgery 45:4, 701-705
CrossRef320
A. Mead, L. Hooper. (2007) Response. Journal of Human Nutrition and Dietetics 20:2, 134-135
CrossRef321
Domingo Hernández, Margarita Rufino, José Manuel González-Posada, Armando Torres, Julio Pascual. (2007) Surrogate end points for graft failure and mortality in kidney transplantation. Transplantation Reviews 21:2, 97-106
CrossRef322
Alex Gatt, Michael Makris. (2007) Hyperhomocysteinemia and Venous Thrombosis. Seminars in Hematology 44:2, 70-76
CrossRef323
Michael Lever, Wendy Atkinson, Peter C.B. Sizeland, Stephen T. Chambers, Peter M. George. (2007) Inter- and intra-individual variations in normal urinary glycine betaine excretion. Clinical Biochemistry 40:7, 447-453
CrossRef324
H.-K. Kuo, K.-C. Liao, S. G. Leveille, J. F. Bean, C.-J. Yen, J.-H. Chen, Y.-H. Yu, T.-Y. Tai. (2007) Relationship of Homocysteine Levels to Quadriceps Strength, Gait Speed, and Late-Life Disability in Older Adults. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 62:4, 434-439
CrossRef325
Naveed Akhtar. (2007) Is Homocysteine a Risk Factor for Atherothrombotic Cardiovascular Disease?. Journal of the American College of Cardiology 49:12, 1370-1371
CrossRef326
W. Klingler, B. Dirks. (2007) Neurologische Notfälle nach Leitsymptomen. Notfall + Rettungsmedizin 10:2, 147-160
CrossRef327
Sanjay Kaul, Andrew A. Zadeh, Prediman K. Shah. (2007) Reply. Journal of the American College of Cardiology 49:12, 1371
CrossRef328
Young-In Kim. (2007) Folate and colorectal cancer: An evidence-based critical review. Molecular Nutrition & Food Research 51:3, 267-292
CrossRef329
Wendy Marcason. (2007) Is Supplementation of B Vitamins Still Recommended to Reduce the Risk of Heart Disease?. Journal of the American Dietetic Association 107:3, 525
CrossRef330
David H Alpers. (2007) Vitamins and prevention of cardiovascular disease and cancer: should we give supplements?. Current Opinion in Gastroenterology 23:2, 159-163
CrossRef331
Naveed Sattar, Philippa Crompton, Lynne Cherry, David Kane, Gordon Lowe, Iain B. McInnes. (2007) Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study. Arthritis & Rheumatism 56:3, 831-839
CrossRef332
A. Blinc, P. Poredoš. (2007) Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease. European Journal of Clinical Investigation 37:3, 157-164
CrossRef333
Antonella Dewell, Dean Ornish. (2007) Plant-based dietary patterns in the control of obesity and cardiovascular risk. Current Cardiovascular Risk Reports 1:1, 9-15
CrossRef334
Mark Messina, Branin Lane. (2007) Soy protein, soybean isoflavones and coronary heart disease risk: where do we stand?. Future Lipidology 2:1, 55-74
CrossRef335
An L. Moens, Marc J. Claeys, Floris L. Wuyts, Inge Goovaerts, Els Van Hertbruggen, Luc C. Wendelen, Viviane O. Van Hoof, Christiaan J. Vrints. (2007) Effect of Folic Acid on Endothelial Function Following Acute Myocardial Infarction. The American Journal of Cardiology 99:4, 476-481
CrossRef336
Paul Nestel. (2007) Nutritional evidence still lacks consistency. Current Opinion in Lipidology 18:1, 1-2
CrossRef337
Martin Buysschaert, Vanessa Preumont, Michel P. Hermans. (2007) Hyperhomocysteinemia and diabetic macroangiopathy: guilty or innocent bystander?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews 1:1, 53-59
CrossRef338
Ka He, Youjia Xu, Linda Van Horn. (2007) The Puzzle of Dietary Fat Intake and Risk of Ischemic Stroke: A Brief Review of Epidemiologic Data. Journal of the American Dietetic Association 107:2, 287-295
CrossRef339
K Zaw, M T Hasan, B Bhowmick, P B Khanna, E A Freeman. (2007) Homocysteine and stroke. Reviews in Clinical Gerontology 17:01,
CrossRef340
Robert Cramb. (2007) Therapy and clinical trials. Current Opinion in Lipidology 18:1, 117-119
CrossRef341
L. Bathum, J. v. B. Hjelmborg, L. Christiansen, M. McGue, B. Jeune, K. Christensen. (2007) Methylenetetrahydrofolate Reductase 677C>T and Methionine Synthase 2756A>G Mutations: No Impact on Survival, Cognitive Functioning, or Cognitive Decline in Nonagenarians. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 62:2, 196-201
CrossRef342
Arturo J Martí-Carvajal, Ivan Solà, Arturo J Martí-Carvajal. 2007. Treatment for anemia in people with AIDS. .
CrossRef343
Yu-Ching Chou, Meei-Shyuan Lee, Mei-Hsuan Wu, Hsiu-Lan Shih, Tsan Yang, Cheng-Ping Yu, Jyh-Cherng Yu, Chien-An Sun. (2007) Plasma homocysteine as a metabolic risk factor for breast cancer: findings from a case–control study in Taiwan. Breast Cancer Research and Treatment 101:2, 199-205
CrossRef344
Malin Hultberg, Björn Hultberg. (2007) Oxidative stress decreases extracellular homocysteine concentration in human hepatoma (HepG2) cell cultures. Chemico-Biological Interactions 165:1, 54-58
CrossRef345
Bradley L. Urquhart, David J. Freeman, J. David Spence, Andrew A. House. (2007) The Effect of Mesna on Plasma Total Homocysteine Concentration in Hemodialysis Patients. American Journal of Kidney Diseases 49:1, 109-117
CrossRef346
J. David Spence. (2007) Intensive management of risk factors for accelerated atherosclerosis: the role of multiple interventions. Current Neurology and Neuroscience Reports 7:1, 42-48
CrossRef347
Matthew T. Rondina, Robert C. Pendleton, Michelle Wheeler, George M. Rodgers. (2007) The treatment of venous thromboembolism in special populations. Thrombosis Research 119:4, 391-402
CrossRef348
Sergio Coccheri. (2007) Approaches to Prevention of Cardiovascular Complications and Events in Diabetes Mellitus. Drugs 67:7, 997-1026
CrossRef349
Anita C.T.M. Peeters, Benien E. van Aken, Henk J. Blom, Pieter H. Reitsma, Martin den Heijer. (2007) The effect of homocysteine reduction by B-vitamin supplementation on inflammatory markers. Clinical Chemistry and Laboratory Medicine 45:1, 54-58
CrossRef350
Sergio Siragusa, Alessandra Malato, Valeria Cigna, Raffaela Anastasio, Lucio Lo Coco, Alessandra Casuccio, Marcello Ciaccio. (2007) The risk of recurrent cardiovascular events in patients with increased plasma homocysteine levels is reduced by short but not long-term therapy with folate and B vitamins. Thrombosis Research 121:1, 51-53
CrossRef351
B.J. Gersh. (2007) Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease. Yearbook of Cardiology 2007, 243-244
CrossRef352
A.A. Rabinstein. (2007) Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease. Yearbook of Neurology and Neurosurgery 2007, 12-14
CrossRef353
Robert Clarke, Sarah Lewington, Paul Sherliker, Jane Armitage. (2007) Effects of B-vitamins on plasma homocysteine concentrations and on risk of cardiovascular disease and dementia. Current Opinion in Clinical Nutrition and Metabolic Care 10:1, 32-39
CrossRef354
L. Norgren, W.R. Hiatt, J.A. Dormandy, M.R. Nehler, K.A. Harris, F.G.R. Fowkes. (2007) Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). European Journal of Vascular and Endovascular Surgery 33:1, S1-S75
CrossRef355
W.H. Frishman. (2007) Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease. Yearbook of Medicine 2007, 315-317
CrossRef356
Pamela Mason. (2007) One is okay, more is better? Pharmacological aspects and safe limits of nutritional supplements. Proceedings of The Nutrition Society 66:4,
CrossRef357
David R. Jacobs, Linda C. Tapsell. (2007) Food, Not Nutrients, Is the Fundamental Unit in Nutrition. Nutrition Reviews 65:10, 439
CrossRef358
Stanley J. Birge. (2007) Nonvertebral "osteoporotic" fractures. Menopause 14:1, 1-2
CrossRef359
Mary Cushman, Barbara M. Alving. 2007. Risk Factors for Cardiovascular Disease and Arterial Thrombosis. , 371-378.
CrossRef360
(2006) Scientific surgery. British Journal of Surgery 93:12, 1567-1567
CrossRef361
Hans-Christoph Diener. (2006) NSA guidelines for management of transient ischaemic attacks. The Lancet Neurology 5:12, 996-997
CrossRef362
M. Malerba, P. Gisondi, A. Radaeli, R. Sala, P.G. Calzavara Pinton, G. Girolomoni. (2006) Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. British Journal of Dermatology 155:6, 1165-1169
CrossRef363
S. J. Moat, A. Madhavan, S. Y. Taylor, N. Payne, R. H. Allen, S. P. Stabler, J. Goodfellow, I. F. W. McDowell, M. J. Lewis, D. Lang. (2006) High- but not low-dose folic acid improves endothelial function in coronary artery disease. European Journal of Clinical Investigation 36:12, 850-859
CrossRef364
Ruth McPherson, Jim Shepherd. (2006) Peering through the darkened glass: success and disappointment in the management of cardiovascular risk. Current Opinion in Lipidology 17:6, 615-618
CrossRef365
Andrea Baccarelli, Antonella Zanobetti, Ida Martinelli, Paolo Grillo, Lifang Hou, Guido Lanzani, Pier Mannuccio Mannucci, Pier Alberto Bertazzi, Joel Schwartz. (2006) Air Pollution, Smoking, and Plasma Homocysteine. Environmental Health Perspectives 115:2, 176-181
CrossRef366
B. Frick, B. Gruber, K. Schroecksnadel, F. Leblhuber, D. Fuchs. (2006) Homocysteine but not neopterin declines in demented patients on B vitamins. Journal of Neural Transmission 113:11, 1815-1819
CrossRef367
Gjin Ndrepepa, Adnan Kastrati, Siegmund Braun, Werner Koch, Klaus Kölling, Julinda Mehilli, Albert Schömig. (2006) A prospective cohort study of predictive value of homocysteine in patients with type 2 diabetes and coronary artery disease. Clinica Chimica Acta 373:1-2, 70-76
CrossRef368
J. David Spence. (2006) Homocysteine and stroke prevention: Have the trials settled the issue?. International Journal of Stroke 1:4, 242-244
CrossRef369
Nur Aksoy, Mehmet Aksoy, Mahmut Cakmak, Hasan Serdar Gergerlioglu, Vedat Davutoglu, Serdar Soydinc, Iclal Meram. (2006) Increased homocysteine in heart failure: a result of renal impairment?. Clinical Chemistry and Laboratory Medicine 44:11, 1324-1329
CrossRef370
Marilena Greco, Fernanda Chiriacò, Piero Del Boccio, Luigi Tagliaferro, Raffaele Acierno, Paola Menegazzi, Eleonora Pinca, Francesco Pignatelli, Carlo Storelli, Giorgio Federici, Andrea Urbani, Michele Maffia. (2006) A proteomic approach for the characterization of C677T mutation of the human gene methylenetetrahydrofolate reductase. PROTEOMICS 6:19, 5350-5361
CrossRef371
Mark Lawrence. (2006) Mandatory folic acid fortification and the science of ‘sociality’. Public Health Nutrition 9:07,
CrossRef372
Young-In Kim. (2006) Does a High Folate Intake Increase the Risk of Breast Cancer?. Nutrition Reviews 64:10, 468-475
CrossRef373
F. Pizzolo, S. Friso, O. Olivieri, N. Martinelli, C. Bozzini, P. Guarini, E. Trabetti, G. Faccini, R. Corrocher, D. Girelli. (2006) Homocysteine, traditional risk factors and impaired renal function in coronary artery disease. European Journal of Clinical Investigation 36:10, 698-704
CrossRef374
Massimo Cigolini, Maria P. Iagulli, Valentino Miconi, Tiziana Lorenzi, Simonetta Lombardi, Giovanni Targher. (2006) Inflammatory variables may mediate the link between low plasma vitamin B6 concentrations and cardiovascular disease in type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases 16:7, e9-e10
CrossRef375
Xavier Pintó. (2006) Vitaminas para disminuir la homocisteína y prevenir las enfermedades cardiovasculares: ¿alimentos o suplementos?. Medicina Clínica 127:14, 535-537
CrossRef376
Ruth McPherson, Jiri Frohlich, George Fodor, Jacques Genest. (2006) Canadian Cardiovascular Society position statement – Recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Canadian Journal of Cardiology 22:11, 913-927
CrossRef377
Paolo Simioni. (2006) Who should be tested for thrombophilia?. Current Opinion in Hematology 13:5, 337-343
CrossRef378
Sanjay Kaul, Andrew A. Zadeh, Prediman K. Shah. (2006) Homocysteine Hypothesis for Atherothrombotic Cardiovascular Disease. Journal of the American College of Cardiology 48:5, 914-923
CrossRef379
J.-M. Garcin, S. Cremades, C. Garcia-Hejl, L. Bordier, O. Dupuy, H. Mayaudon, B. Bauduceau. (2006) Is Hyperhomocysteinemia an Additional Risk Factor of the Metabolic Syndrome?. Metabolic Syndrome and Related Disorders 4:3, 185-195
CrossRef380
Marie-Hélène Pesant, Jean-Patrice Baillargeon. (2006) Comparing rosiglitazone with ethinylestradiol/cyproterone acetate in the treatment of polycystic ovary syndrome. Expert Review of Obstetrics & Gynecology 1:1, 81-92
CrossRef381
Matthew A. Roberts, David L. Hare, Sujiva Ratnaike, Francesco L. Ierino. (2006) Cardiovascular Biomarkers in CKD: Pathophysiology and Implications for Clinical Management of Cardiac Disease. American Journal of Kidney Diseases 48:3, 341-360
CrossRef382
Huyen Tran, Graeme J. Hankey, John W. Eikelboom. (2006) Homocysteine-Should We Screen and Treat in Preventive Cardiology Programs?. Journal of Cardiopulmonary Rehabilitation 26:5, 281-287
CrossRef383
Pierre Théroux, Benoît Labarthe. (2006) Coping with new challenges in acute coronary syndromes. Canadian Journal of Cardiology 22, 13C-20C
CrossRef384
Iftikhar J Kullo. (2006) HOPE 2: can supplementation with folic acid and B vitamins reduce cardiovascular risk?. Nature Clinical Practice Cardiovascular Medicine 3:8, 414-415
CrossRef385
(2006) Homocysteine, B Vitamins, and Cardiovascular Disease. New England Journal of Medicine 355:2, 205-211
Full Text386
Michaela Diamant, Maarten E. Tushuizen. (2006) The metabolic syndrome and endothelial dysfunction: Common highway to type 2 diabetes and CVD?. Current Diabetes Reports 6:4, 279-286
CrossRef387
Philip R. Liebson. (2006) Women's Health Initiative (WHI) Dietary Trial and Norwegian Vitamin Trial (NORVIT). Preventive Cardiology 9:3, 178-182
CrossRef388
Loscalzo, Joseph, . (2006) Homocysteine Trials — Clear Outcomes for Complex Reasons. New England Journal of Medicine 354:15, 1629-1632
Full Text389
Bønaa, Kaare Harald, Njølstad, Inger, Ueland, Per Magne, Schirmer, Henrik, Tverdal, Aage, Steigen, Terje, Wang, Harald, Nordrehaug, Jan Erik, Arnesen, Egil, Rasmussen, Knut, . (2006) Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction. New England Journal of Medicine 354:15, 1578-1588
Full Text390
Cynthia M Carlsson. (2006) Homocysteine Lowering with Folic Acid and Vitamin B Supplements. Drugs & Aging 23:6, 491-502
CrossRef391
Reynold Spector, Elliot S. Vesell. (2006) The Heart of Drug Discovery and Development: Rational Target Selection. Pharmacology 77:2, 85-92
CrossRef
- Letters
